## **Accepted Manuscript**

Submission Date: 2023-09-27 Accepted Date: 2023-10-20 Accepted Manuscript online: 2023-10-26

# **European Journal of Pediatric Surgery**

# Bridging the Gap: Reporting Baseline Characteristics, Process and Outcome Parameters in Hirschsprung's Disease. A Systematic Review.

Daniel Rossi, Anna L Granström, Nadine M Teunissen, Rene Wijnen, Tomas Wester, Cornelius Sloots.

Affiliations below.

DOI: 10.1055/a-2198-9050

**Please cite this article as:** Rossi D, Granström A L, Teunissen N M et al. Bridging the Gap: Reporting Baseline Characteristics, Process and Outcome Parameters in Hirschsprung's Disease. A Systematic Review. European Journal of Pediatric Surgery 2023. doi: 10.1055/a-2198-9050

**Conflict of Interest:** The authors declare that they have no conflict of interest.

#### Abstract:

#### Introduction

The variation in standardized, well-defined parameters in Hirschsprung's disease (HSCR) research hinders overarching comparisons and complicates evaluations of care quality across healthcare settings. This review addresses the significant variability observed in these parameters as reported in recent publications. The goal is to compile a list of commonly described baseline characteristics, process and outcome measures, and to investigate disparities in their utilization and definitions.

#### Materials and methods

A systematic review of literature on the primary care process for HSCR was performed according to PRISMA guidelines. Relevant literature published between 2015 and 2021 was obtained by combining the search term "Hirschsprung's disease" with "treatment outcome", "complications", "mortality", "morbidity", "survival" in Medline, Embase and the Cochrane Library. We extracted study characteristics, reported process and outcome parameters, and patient and disease characteristics.

#### Results

We extracted 1026 parameters from 200 publications and categorized these into patient characteristics (n=226), treatment and care process characteristics (n=199), and outcomes (n=601). 116 parameters were reported in more than 5% of publications. The most frequently reported characteristics were sex (88%), age at surgery (66%), postoperative Hirschsprung-associated enterocolitis (64%), type of repair (57%), fecal incontinence (54%), and extent of aganglionosis (51%).

#### Conclusion

This review underscores the pronounced variation in reported parameters within HSCR studies, highlighting the necessity for consistent, well-defined measures and reporting systems in order to foster improved data interpretability. Moreover, it advocates for the use of these findings in the development of a Core Indicator Set, complementing the recently developed Core Outcome Set. This will facilitate quality assessments across pediatric surgical centers throughout Europe.

#### **Corresponding Author:**

Daniel Rossi, Erasmus MC, Pediatric Surgery, Dr. Molewaterplein 40, 3000 CA Rotterdam, Netherlands, d.rossi@erasmusmc.nl, daan. rossi@gmail.com

#### Affiliations:

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.




Daniel Rossi, Erasmus MC, Pediatric Surgery, Rotterdam, Netherlands
Daniel Rossi, Karolinska Institute, Department of Women's and Children's Health, Stockholm, Sweden
Anna L Granström, Karolinska Institutet, Department of Women's and Children's Health, Stockholm, Sweden
[...]

Cornelius Sloots, Erasmus MC Sophia, Pediatric Surgery, Rotterdam, Netherlands



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.





#### **INTRODUCTION**

Hirschsprung's disease (HSCR) is a rare congenital condition that affects 1 in 5000 newborn children. It is characterized by the absence of ganglion cells in the enteric nervous system of the rectum, with variable involvement of the colon and small bowel. Current understanding suggests that this abnormality arises from disruptions in embryonic development stages, particularly the migration and survival of enteric nervous system precursor cells<sup>1,2</sup>.

Infants with HSCR present with symptoms of functional intestinal obstruction, such as delayed passage of meconium, abdominal distention, vomiting, and chronic constipation. Currently, establishing the diagnosis predominantly relies on rectal suction biopsies revealing an absence of ganglion cells. Aimed at re-establishing regular bowel functionality, the treatment generally involves resection of the aganglionic colon segment and reconnecting the ganglionic intestine segment to the anus. Surgical strategies include the Swenson<sup>3</sup>, Duhamel<sup>4</sup>, and Soave-Boley<sup>5,6</sup> resection techniques, fashioned as single- or multi-stage, open, laparoscopic, or total transanal procedures<sup>1,7</sup>.

Due to the rarity of HSCR, prospective, controlled, multi-center trials with adequate patient numbers are notably scarce. Furthermore, despite the increase in HSCR-related publications in recent decades, which could potentially contribute to more evidence-based practice, the usability of these research findings is limited. This limitation stems from the substantial variability in the reported research parameters and their respective definitions, preventing the possibility of comprehensive comparisons. Although a HSCR core outcome set has been

formulated, this has not yet attained widespread recognition or utilization within the scholarly community<sup>7,8</sup>. These circumstances further prevent the resolution of existing evidence gaps, particularly in understanding short-term complications and long-term interactions between functional outcomes and quality of life<sup>9</sup>. Presently, guidelines for the management of HSCR often rely on expert opinion or consensus rather than comprehensive research, which implies that there is substantial room for improvement in the evidence-based practice.

The lack of standardized, well-defined parameters not only hinders overarching comparisons in research, but also adds complexity to the evaluation and comparison of (quality of) HSCR care across hospitals, regions, or even countries. A pivotal step in advancing HSCR care has been the initiation of the European Pediatric Surgical Audit (EPSA) for several congenital malformations, including HSCR. This quality-of-care measurement tool for clinicians makes use of quality indicators to reliably identify, monitor, and evaluate variation in clinical practices and outcomes 10-12. Improvement efforts could then be aligned with the findings from this evaluation. Indicators can be classified into three categories-structure indicators, process indicators, and outcome indicators-each evaluating different aspects of the care pathway. Examples of structure indicators are patient volumes and the availability of certain imaging techniques. Process indicators can involve factors such as the elapsed time between diagnosis and surgery, and the proportion of patients undergoing a particular diagnostic test. Outcome indicators might encompass elements such as survival rates or complication rates<sup>13</sup>. To develop a universally acknowledged set of quality indicators for evaluating and identifying variations in the quality of care for HSCR patients, it is essential to ascertain which parameters are

considered most important by HSCR researchers and clinicians treating this disease. These identified outcomes can then serve as the basis for a consensus-driven process to delineate the new set of quality indicators. This initiative requires comprehensive understanding of all possible outcomes highlighted in HSCR research, as well as patient characteristics and treatment and care process characteristics, in order to adjust for case variability when comparing care quality. Such endeavors could provide an even deeper understanding of interhospital variability, further supporting future advancements in the care of this patient population.

The primary objective of this study was to compile a list of outcome measures described in recent peer-reviewed publications on HSCR and to explore the discrepancies in their utilization, definition, and reporting. The secondary objective was to identify patient characteristics and treatment and care process characteristics that would facilitate a more informed interpretation of future comparative analysis results.

#### **MATERIALS AND METHODS**

This review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement and guidelines<sup>14</sup>. We developed a comprehensive search strategy in collaboration with a medical librarian of the Erasmus University Medical Center. The search was based on the search term 'Hirschsprung's disease', combined with the terms 'morbidity' or 'mortality' or 'survival' or 'outcome' or 'complication'. The search criteria were applied to the databases Medline, Embase, and the Cochrane Library. Duplicate publications

were removed and subsequently all studies published from 2015 up to and September 2021 were selected. Complete search strategies are provided in Supplementary Material 1. The search was performed in October 2021.

#### Inclusion and exclusion criteria

All publications related to any aspect of the main HSCR care process, including surgical and non-surgical management, were included. To ensure contemporaneousness, papers published before the year 2015 were excluded. Other criteria for exclusion were the following: non-English-language publications, animal research, in vitro studies, case series with fewer than ten patients, editorials, letters, meeting abstracts, reviews, guidelines, and consensus statements.

#### Selection process

Four reviewers participated in the selection process of the publications. NT and AG separately screened the titles and abstracts of all publications resulting from the search to determine their suitability in terms of reporting on the care for and management of patients with HSCR. NT, DR and AG then independently reviewed the full texts of the selected publications to ascertain their relevance to the study. Any disagreements were resolved by TW, who served as a third reviewer. The reviewing authors were not blinded to the title, authors, or journal names during the screening process.

#### Data collection, analysis and reporting

DR and NT performed the data extraction, which included recording the origin and year of publications, study design, the number of included patients per study (as shown in Table 1) and all relevant parameters in a primary Excel-based framework. Parameters were categorized and, when feasible, merged based on consensus among the reviewers. For each parameter, the number of publications in which it was mentioned and the proportion relative to the total number of included publications were calculated. The parameters mentioned in more than 5% of the included publications were then recorded in a separate Excel file. Additionally, all definitions of studied parameters were extracted, as well as the types of instruments or tools, either standardized or not, with which the parameters were assessed, such as medical scores, scales and questionnaires. This review did not include the extraction or interpretation of parameter estimates, nor did it involve the evaluation and assessment of methodological quality of the included publications. Statistical analyses were conducted utilizing a customized data computational approach implemented within the Excel environment.

#### **RESULTS**

#### **Included publications**

The search strategy resulted in 1254 publications. After removal of duplicates and limiting the results to articles published between 2015 and 2021, 828 articles remained, of which 200 met the inclusion criteria (Figure 1). The study characteristics of all included publications are summarized in Table 1. An individualized overview of included studies and corresponding study characteristics can be found in Supplementary Material 2.

#### Data extraction

Full-text analysis of the 200 included publications identified 1026 studied parameters described in at least one of the included publications. The parameters were categorized into patient characteristics (n=226), treatment and care process characteristics (n=199), and outcomes (n=601). As several parameters could arguably be included in more than one category, categorization followed agreement between the first two authors. To facilitate the comparison of variation in studied parameters within similar subjects, we further arranged the parameters by topic, such as comorbidities, primary treatment, specific complications and long-term outcome. A list of all identified, categorized items is attached in Supplementary Material 3-5.

#### Measured parameters

Of the 1026 identified studied parameters, 116 were described in at least 5% of included publications (Table 2). Predominantly described patient characteristics were sex (88%), age at surgery (66%), and the extent of aganglionosis (histological level of transitional zone, 50.5%). Frequently studied treatment and care process characteristics included the type of repair (56.5%), duration of follow-up (39%) and preoperative stoma (35.5%). The most frequently mentioned outcome measures were postoperative Hirschsprung-associated enterocolitis (HAEC) (63.5%), incontinence (53.5%) and constipation (48%). The primarily described complications after surgical treatment were anastomotic stricture and anastomotic leakage, cited in 38% and 28% of the publications, respectively. Other significant areas of focus encompassed length of primary hospital stay (highlighted in 35.5% of the studies), mortality (26.5%), reoperation rate (42.5%) and readmission rate (12.5%). Because the definitions of analyzed parameters and the used (standardized) measurement tools diverged significantly

across different publications, it was challenging to derive clear-cut definitions or compare these results. Consequently these results specifically concerning the definitions of the extracted parameters are not delineated in this report. An overview of the standardized clinical tools, scores and scales applied in the studies is presented in Table 3.

#### **DISCUSSION**

This study aimed to create a comprehensive overview of patient characteristics, treatment and care process characteristics, and outcome measures. To our knowledge, it represents the first attempt to compile such an extensive summary of parameters investigated in HSCR research. From the 200 publications on HSCR spanning from 2015 to 2021 that were included, we identified a total of 1026 unique studied parameters, which could be categorized into 226 patient characteristics, 199 treatment and care process characteristics, and 601 outcomes. Among these, 116 parameters were described in at least 5% of the included publications, of which only six mentioned in more than 50% of the included publications. These six parameters were postoperative HAEC, incontinence, type of repair, sex, age at surgery, and extent of aganglionosis.

The current body of research of interest for this review primarily consists of retrospective, single-center studies with low patient volumes<sup>15</sup>. A substantial portion of the surveyed literature (69%) is based on data derived from cohorts comprising fewer than 100 patients, and more than three-quarters of the studies are single-center studies. This underscores the need for more multi-center and prospective studies involving larger patient cohorts to yield more robust

results. Such approaches may include randomized controlled trials or the implementation of standardized data collection within patient registries, such as clinical audits. This study also confirms that contemporary research on HSCR tends to focus more on outcomes (59% of extracted variables) rather than on characteristics used to evaluate care processes (19%), and more on short-term than on long-term outcomes. Furthermore, considering the 1026 distinct parameters mentioned in the included publications, we substantiated that data collection and reporting lacks uniformity across studies, making it harder to consolidate and analyze findings cohesively. We also demonstrated substantial variation in parameter definitions and the tools used across studies to measure important parameters such as quality of life or other patientreported outcome measures (PROMs)<sup>16</sup>, as illustrated in Table 3. This lack of uniformity hinders comparing and contrasting of results across different studies, and once more indicates an urgent need for creating and implementing standardized, reliable and well-defined parameters and tools that are both patient-centric and disease-specific. Concurrently, it is essential to acknowledge that the NETS1HD study introduced a novel HSCR core outcome set through rigorous methods<sup>7</sup>. In contrast to this study, our approach not only centered on outcome measures but also encompassed a comprehensive analysis of treatment and diagnostic characteristics, as well as patients' baseline characteristics. We focused on identifying the most extensively studied parameters and did not consult a panel of experts for their ratings and definitions. Promoting the adoption of this core outcome set and similar initiatives and implementing these standardized data sets in both large and small pediatric surgical studies is crucial, as it will enhance relevance, minimizes bias, and facilitate future meta-analyses.

Standardization of research parameters is especially important in rare disease research, as the rare nature of the studied conditions often inherently complicates generating high-quality evidence, as we have confirmed with this review. Because of the demonstrated lack of highquality evidence, current guidelines and clinical practices still predominantly hinge on expert opinions and consensus statements. Moreover, as opposed to the previously mentioned HSCR core outcome set, which was developed to standardize research, it is vital to acknowledge the current deficit in standardized measures for evaluating the quality of HSCR care and the absence of a common benchmarking system. In the modern healthcare landscape there is a growing emphasis on the quality of provided care, and standardized measures are essential for precise benchmarking and the accurate interpretation of outcomes. Consequently, the development and implementation of standardized benchmarking through measuring predefined quality indicators could significantly enhance the overall quality of HSCR care. Current clinical guidelines and consensus statements and the list of treatment and care process characteristics and outcomes resulting from this systematic review may function as a starting point for a consensus method to develop quality indicator sets for such tools, involving both the international HSCR expert community as well as patient representatives. The European Reference Network for Inherited Congenital Anomalies and its registry (EPSA) have the potential to play a critical role in the more effective collection and analysis of comparative quality data, ultimately leading to the establishment of best practices and bridging the gap between short-term and long-term outcomes<sup>10</sup>.

By adhering to the PRISMA guidelines, we ensured a structured and transparent methodology. The extensive data extraction and categorization allowed for interpretation of the current most important parameters for clinical researchers in the field. This approach has markedly reduced the likelihood of overlooking crucial parameters, as we have included all parameters mentioned in at least 5% of the selected studies. Our findings emphasize the necessity for standardization of data collection, definitions and use of clinical tools and instruments. By addressing a significant gap in HSCR research-namely the lack of uniformity in parameter measurement and reporting methods-we not only bring to light the existing discrepancies but underscore the urgency for a cohesive approach in future studies. Additionally, the resulting list could lay the groundwork for determining which parameters are important for assessing the quality of HSCR care. Our research also has some limitations. Firstly, as we pooled data from children and adults without providing a distinct analysis for each group, the findings are not age-specific. It is recommendable to study the functional changes HSCR patients undergo throughout their lifespans. Secondly, our research is limited by a specific time frame, focusing solely on studies published between 2015 and 2021. While this provides insight into recent clinical practices, it may overlook critical insights from publications after 2021. Thirdly, although we identified significant variations in definitions, the abundance of these definitions prevented us from exhaustively detailing each one.

As we are transitioning into prioritizing evidence-based practice and patient-centered outcomes, embracing a unified approach and adopting quality indicators are crucial. This approach will not only refine our understanding and management of HSCR but also fortify the

foundations of pediatric surgical research, driving meaningful advancements in pediatric patient care.

#### **CONCLUSION**

This review highlights the substantial variation in the reporting of patient characteristics and outcomes in Hirschsprung's disease research, with 1026 parameters identified in recent literature. It suggests an urgent need for adopting the newly developed core outcome set, and establishing a standardized core indicator set. The comprehensive list of studied parameters identified in our review can facilitate this process. Implementing standardized measurement and reporting systems is vital, promising enhanced interpretability of results and the potential for effective quality-of-care benchmarking across pediatric surgical centers in Europe. Looking ahead, the European Pediatric Surgery Audit (EPSA) emerges as a crucial entity to realize this vision, heralding a new era in pediatric surgical research and care.

#### **CONTRIBUTIONS**

The study was designed by DR, AG, NT, TW and RW. Inclusion and exclusion criteria, assessment strategy, and the utilized Excel-based data extraction framework were developed by all authors. NT developed the search strategy, and NT, DR and AG were responsible for screening, as well as data extraction and analyses. DR drafted the manuscript; all authors read, provided feedback, and approved the final manuscript.

#### **FUNDING**

The European Commission funded the EPSA|ERNICA Registry in the 3<sup>rd</sup> Health Program, HP-PJ-2019, and 4<sup>th</sup> Health Program, EU4H-2022-PJ.

#### **CONFLICT OF INTEREST**

None declared.

#### **REFERENCES**

- 1. Kyrklund K, Sloots CEJ, de Blaauw I, et al. ERNICA guidelines for the management of rectosigmoid Hirschsprung's disease. *Orphanet J Rare Dis.* Jun 25 2020;15(1):164. doi:10.1186/s13023-020-01362-3
- 2. Chhabra S, Harwood R, Kenny SE. Hirschsprung's disease. *Surgery (Oxford)*. 2019;37(11):640-645. doi:10.1016/j.mpsur.2019.09.005
- 3. Swenson O, Bill AH, Jr. Resection of rectum and rectosigmoid with preservation of the sphincter for benign spastic lesions producing megacolon; an experimental study. *Surgery*. Aug 1948;24(2):212-20.
- 4. Duhamel B. A new operation for the treatment of Hirschsprung's disease. *Arch Dis Child*. Feb 1960;35(179):38-9. doi:10.1136/adc.35.179.38
- 5. Soave F. A NEW SURGICAL TECHNIQUE FOR TREATMENT OF HIRSCHSPRUNG'S DISEASE. *Surgery*. Nov 1964;56:1007-14.
- 6. Boley SJ. NEW MODIFICATION OF THE SURGICAL TREATMENT OF HIRSCHSPRUNG'S DISEASE. *Surgery*. Nov 1964;56:1015-7.
- 7. Allin BSR, Bradnock T, Kenny S, et al. NETS(1HD) study: development of a Hirschsprung's disease core outcome set. *Arch Dis Child*. Dec 2017;102(12):1143-1151. doi:10.1136/archdischild-2017-312901
- 8. Owens E. The qualitative and quantitative outcomes of children with Hirschsprung's Disease and Anorectal Malformations. University of Liverpool; 2023.
- 9. Davidson JR, Kyrklund K, Eaton S, et al. Long-term surgical and patient-reported outcomes of Hirschsprung Disease. *J Pediatr Surg.* Sep 2021;56(9):1502-1511. doi:10.1016/j.jpedsurg.2021.01.043
- 10. Teunissen NR, D; Wouters, M.W.; Eaton, S; van Heurn, E.; Wijnen, R; on behalf of the EPSA| ERNICA Registry Group. The European Paediatric Surgical Audit: improving the quality of care in rare congenital malformations.
- 11. van Heurn E, de Blaauw I, Heij H, et al. Quality Measurement in Neonatal Surgical Disorders: Development of Clinical Indicators. *Eur J Pediatr Surg*. Dec 2015;25(6):526-31. doi:10.1055/s-0034-1396416
- 12. Beck N, van Bommel AC, Eddes EH, et al. The Dutch Institute for Clinical Auditing: Achieving Codman's Dream on a Nationwide Basis. *Ann Surg*. Apr 2020;271(4):627-631. doi:10.1097/SLA.0000000000003665
- 13. Donabedian A. Evaluating the quality of medical care. 1966. *Milbank Q*. 2005;83(4):691-729. doi:10.1111/j.1468-0009.2005.00397.x

- 14. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *Bmj.* 2021;doi:10.1136/bmj.n160
- 15. Allin BSR, Opondo C, Bradnock TJ, et al. Outcomes at five to eight years of age for children with Hirschsprung's disease. *Arch Dis Child*. Nov 2 2020;106(5):484-90. doi:10.1136/archdischild-2020-320310
- 16. Besner AS, Ferreira JL, Ow N, et al. Patient-reported outcome measures in pediatric surgery A systematic review. *J Pediatr Surg*. May 2022;57(5):798-812. doi:10.1016/j.jpedsurg.2021.12.036

**Figure 1.** PRISMA Flowchart: systematic review of studied parameters in Hirschsprung's disease research



#### **SUPPLEMENTARY 1: search strategy**

#### Embase.com

('Hirschsprung disease'/de OR (Hirschsprung\* OR Hirschprung\* OR ((aganglion\*) NEAR/3 (colon\* OR intestin\* OR megacolon\* OR rectosigmoid\*)) OR ((congenit\* OR idiopathic\*) NEAR/3 (megacolon\*)) OR megasigmoid\*):ab,ti,kw) AND ('morbidity'/exp OR 'mortality'/exp OR 'survival'/exp OR 'health care quality'/de OR 'benchmarking'/de OR 'clinical indicator'/de OR 'performance measurement system'/de OR 'practice guideline'/de OR 'clinical pathway'/de OR 'clinical protocol'/de OR 'consensus development'/de OR 'professional standard'/exp OR 'treatment outcome'/exp OR 'complication'/exp OR (morbidit\* OR mortalit\* OR surviv\* OR benchmark\* OR bench-mark\* OR clinical-indicat\* OR performance-measurement-system\* OR guideline\* OR clinical-pathway\* OR (clinical\* NEAR/3 protocol\*) OR consensus\* OR professional-standard\* OR audit OR audits OR outcome\* OR complication\*):ab,ti,kw) NOT ([conference abstract]/lim OR [editorial]/lim OR [letter]/lim) AND [English]/lim NOT ( 'review'/exp OR (review):ti) NOT ((animal/exp OR animal\*:de OR nonhuman/de) NOT ('human'/exp)) AND [2015-2021]/py

#### Medline (Ovid)

(Hirschsprung Disease/ OR (Hirschsprung\* OR Hirschprung\* OR ((aganglion\*) ADJ3 (colon\* OR intestin\* OR megacolon\* OR rectosigmoid\*)) OR ((congenit\* OR idiopathic\*) ADJ3 (megacolon\*)) OR megasigmoid\*).ab,ti,kf.) AND (Morbidity/ OR exp Mortality/ OR mortality.fx. OR Survival/ OR Quality of Health Care/ OR Benchmarking/ OR Practice Guideline/ OR Critical Pathways/ OR Clinical Protocols/ OR Consensus/ OR Standard of Care/ OR exp Treatment Outcome/ OR (morbidit\* OR mortalit\* OR surviv\* OR benchmark\* OR bench-mark\* OR clinical-indicat\* OR performance-measurement-system\* OR guideline\* OR clinical-pathway\* OR (clinical\* ADJ3 protocol\*) OR consensus\* OR professional-standard\* OR audit OR audits OR outcome\* OR complication\*).ab,ti,kf.) NOT (letter\* OR news OR comment\* OR editorial\* OR congres\* OR abstract\* OR book\* OR chapter\* OR dissertation abstract\*).pt. AND english.lg. NOT (exp Review/ OR (review).ti.) NOT (exp animals/ NOT humans/)

#### **Cochrane Central**

((Hirschsprung\* OR Hirschprung\* OR ((aganglion\*) NEAR/3 (colon\* OR intestin\* OR megacolon\* OR rectosigmoid\*)) OR ((congenit\* OR idiopathic\*) NEAR/3 (megacolon\*)) OR megasigmoid\*):ab,ti,kw) AND ((morbidit\* OR mortalit\* OR surviv\* OR benchmark\* OR bench NEXT mark\* OR clinical NEXT indicat\* OR performance NEXT measurement NEXT system\* OR guideline\* OR clinical NEXT pathway\* OR (clinical\* NEAR/3 protocol\*) OR consensus\* OR professional NEXT standard\* OR audit OR audits OR outcome\* OR complication\*):ab,ti,kw)

SUPPLEMENTARY 2: included publications

Author	Title	Y e a r	Con tine nt	n =	Study	n	
Aubdoo llah T, et al.	Clinical outcomes and ergonomics analysis of three laparoscopic techniques for Hirschsprung's disease	2 0 1 5	Asia	9	Co mpa rativ e	Ret ros pec tive	Co hort
Aubdoo llah T, et al.	Hybrid Single-Incision Laparoscopic Approaches for Endorectal Pull-Through in Hirschsprung's Disease	2 0 1 5	Asia	3 6	Obs erva tion al	Ret ros pec tive	Co hort
Chung P, et al.	Clinical and manometric evaluations of anorectal function in patients after transanal endorectal pull-through operation for Hirschsprung's disease: A multicentre study	2 0 1 5	Asia	3 7	Co mpa rativ e	Ret ros pec tive	Co hort
Deng X, et al.	Comparative Analysis of Modified Laparoscopic Swenson and Laparoscopic Soave Procedure for Short-Segment Hirschsprung Disease in Children	2 0 1 5	Asia	4 2	Co mpa rativ e	Ret ros pec tive	Co hort
Graneli C, et al.	Development of Frequency of Stools over Time in Children with Hirschsprung Disease Posttransanal Endorectal One-Stage Pull-through	2 0 1 5	Eur ope	3 1	Obs erva tion al	Pro spe ctiv e	Ca se- con trol
Granstr öm A, et al.	Adult outcomes after surgery for Hirschsprung's disease: Evaluation of bowel function and quality of life	2 0 1 5	Eur ope	3 9	Co mpa rativ e	Ret ros pec tive	Ca se- con trol
Hukkin en M, et al.	Postoperative outcome and survival in relation to small intestinal involvement of total colonic aganglionosis	2 0 1 5	Eur ope	2	Co mpa rativ e	Pro spe ctiv e	Co hort
Khalil M	Long-term health-related quality of life for patients with Hirschsprung's disease at 5 years after transanal endorectal pull-through operation	2 0 1 5	Afric a	5 3	Obs erva tion al	Pro spe ctiv e	Co hort
Khazdo uz M, et al.	Clinical outcome and bowel function after surgical treatment in Hirschsprung's disease	2 0 1 5	Asia	1 6 1	Obs erva tion al	Pro spe ctiv e	Co hort
Martíne z- Criado Y, et al.	Results of transanal endorrectal descent in Hirschsprung's disease	2 0 1 5	Eur ope	7	Obs erva tion al	Ret ros pec tive	Co hort
Miyano G, et al.	Rectal mucosal dissection commencing directly on the anorectal line versus commencing above the dentate line in laparoscopy-assisted transanal pull-through for Hirschsprung's disease: Prospective medium-term follow-up	2 0 1 5	Asia	7	Co mpa rativ e	Ret ros pec tive	Co hort
Stensru d K, et al.	Anal endosonography and bowel function in patients undergoing different types of endorectal pull-through procedures for Hirschsprung disease	2 0 1 5	Eur ope	5 2	Obs erva tion al	Pro spe ctiv e	Co hort
van den Hondel D, et al.	Psychosexual Well-Being after Childhood Surgery for Anorectal Malformation or Hirschsprung's Disease	2 0 1 5	Eur ope	3 6	Obs erva tion al	Ret ros pec tive	Co hort
Wang H, et al.	Nursing Intervention for Outpatient Rehabilitation in Pediatric Patients with Hirschsprung Disease after Colectomy	2 0 1 5	Asia	8 5	Co mpa rativ e	Ret ros pec tive	Tria I
Wester T, et al.	Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease	2 0 1 5	Eur ope	1 8	Obs erva tion al	Ret ros pec tive	Co hort
Xiong X, et al.	Long term quality of life in patients with Hirschsprung's disease who underwent heart-shaped anastomosis during childhood: A twenty-year follow-up in China	2 0 1	Asia	9 2	Co mpa rativ	Ret ros pec	Ca se- con

		5			е	tive	trol
Ladi-	A comparative study of transcutaneous interferential electrical stimulation plus	2	Asia	3	Co	Ret	Tria
Seyedi	behavioral therapy and behavioral therapy alone on constipation in	0	7.514	ő	mpa	ros	
an S, et	postoperative Hirschsprung disease children	1			rativ	pec	'
al.		6			е	tive	
Aworan	Does Functional Outcome Improve with Time Postsurgery for Hirschsprung	2	Eur	5	Obs	Pro	Co
ti O, et	Disease?	0	ope	1	erva	spe	hort
al.		1			tion	ctiv	
		6			al	е	
Banasi	3D high-definition manometry in evaluation of children after surgery for	2	Eur	1	Co	Ret	Co
uk M,	Hirschsprung's disease: A pilot study	0	ope	4	mpa	ros	hort
et al.		1			rativ	pec	
		6			е	tive	
Chen	Pathological changes of interstitial cells of Cajal and ganglion cells in the	2	Asia	5	Co	Ret	Co
X, et al.	segment of resected bowel in Hirschsprung's disease	0	· ·	8	mpa	ros	hort
		1			rativ	pec	
Chia C	Fridamialary of Hisashary wells Disasas in Taiwanasa Children A 12 year	6	A = i =	_	e Oha	tive	-
Chia S,	Epidemiology of Hirschsprung's Disease in Taiwanese Children: A 13-year	2	Asia	6	Obs	Ret	Co
et al.	Nationwide Population-based Study	0		9	erva	ros	hort
		6		9	tion al	pec	
Feng	Rates and burden of surgical site infections associated with pediatric colorectal	2	Nort	4	Obs	Ret	Co
C, et al.	surgery: Insight from the National Surgery Quality Improvement Program	0	h-	5	erva	ros	hort
o, et al.	Jangery. Insight from the Mattorial Jurgery Quality Improvement Frogram	1	Ame	7	tion	pec	11011
		6	rica	l '	al	tive	
Granstr	Population-based study shows that Hirschsprung disease does not have a	2	Eur	3	Co	Ret	Co
öm A,	negative impact on education and income	0	ope	8	mpa	ros	hort
et al.	megative impact on education and moone	1	ОРО	9	rativ	pec	11011
3.5		6		-	е	tive	
Imvised	Multicenter experience of primary transanal endorectal pull-through operation	2	Asia	7	Obs	Ret	Co
T, et al.	in childhood Hirschsprung's disease	0		6	erva	ros	hort
,		1			tion	pec	
		6			al	tive	
Li Q, et	The mid-term outcomes of TRM-PIAS, proctocolectomy and ileoanal	2	Asia	1	Co	Ret	Co
al.	anastomosis for total colonic aganglionosis	0		9	mpa	ros	hort
		1			rativ	pec	
		6			е	tive	
Lukač	Effectiveness of various surgical methods in treatment of Hirschsprung's	2	Eur	8	Co	Pro	Со
M, et	disease in children	0	ope	4	mpa	spe	hort
al.		1			rativ	ctiv	
		6		_	e	е	
Muller	Long-Term Outcome of Laparoscopic Duhamel Procedure for Extended	2	Eur	3	Obs	Ret	Со
C, et al.	Hirschsprung's Disease	0	ope	0	erva	ros	hort
		6			tion	pec	
O'Hare	A Retrospective Cohort Study of Total Colonic Aganglionosis: Is the Appendix	2	Eur	9	al Obs	tive Pro	Co
T, et al.	a Reliable Diagnostic Tool?	0	ope	1	erva	spe	hort
i, et al.	a Nellable Diagnostic 1001:	1	Ope	+	tion	ctiv	Hort
		6			al	e	
Onishi	Long-term outcome of bowel function for 110 consecutive cases of	2	Asia	1	Obs	Pro	Co
S, et al.	Hirschsprung's disease: Comparison of the abdominal approach with transanal	0		1	erva	spe	hort
	approach more than 30 years in a single institution – is the transanal approach	1		0	tion	ctiv	
	truly beneficial for bowel function?	6			al	е	
Oulads	How to manage a late diagnosed Hirschsprung's disease	2	Afric	1	Obs	Pro	Co
aiad M		0	a	5	erva	spe	hort
		1			tion	ctiv	
		6			al	е	
Singh	Congenital Neonatal Intestinal Obstruction: Retrospective Analysis at Tertiary	2	Asia	1	Obs	Ret	Co
V, et al.	Care Hospital	0		7	erva	ros	hort
		1			tion	pec	
Cocco	Are there any factors influencing the course of multistage treatment in	6	Eur	2	al	tive	Ca
Sosno	Are there any factors influencing the course of multistage treatment in	2	Eur	2	Co	Ret	Co
wska Dotal	Hirschsprung's disease?	0	ope	9	mpa	ros	hort
P, et al.		6			rativ	pec	
van	Children with congenital colorectal malformations often require special	2	Eur	2	e Obs	tive Pro	Co
van den	education or remedial teaching, despite normal intelligence	0	ope	0	erva	spe	hort
Hondel	addeduction of remodular teaching, despite normal intelligence	1	Ope		tion	ctiv	11011
TRAINGE			1				
D, et al.		6	l	ı	al	е	

Xia X,	Single-incision laparoscopic versus conventional laparoscopic surgery for	2	Asia	7	Со	Ret	Со
et al.	Hirschsprung's disease: A comparison of medium-term outcomes	0	71314	5	mpa	ros	hort
		1		-	rativ	pec	
		6			е	tive	
Yang	Prognostic factors in children with total colonic aganglionosis treated with the	2	Asia	4	Obs	Ret	Co
S, et al.	soave procedure: The experience of 43 patients from a single institution	0		3	erva	ros	hort
		1			tion	pec	
		6			al	tive	
Zarei T,	Evaluation of Hirschsprung's disease in a pediatric hospital in southern Iran	2	Asia	4	Obs	Ret	Co
et al.	during 2005-2013	0		2	erva	ros	hort
		1		5	tion	pec	
		6			al	tive	
Adıgüz	Transanal endorectal pull-through for Hirschsprung's disease: experience with	2	Eur	5	Obs	Ret	Co
el U, et	50 patients	0	asia	0	erva	ros	hort
al.		1 7			tion	pec	
Dina V	Transport multiple control Control and Company to chair up for modicitie nations	7	A = i =	1	al	tive	-
Bing X,	Transanal pullthrough Soave and Swenson techniques for pediatric patients with Hirschsprung disease	2 0	Asia	1 4	Obs	Ret	Co
et al.	with miscrispiding disease	1		8	erva tion	ros	hort
		7		0	al	pec tive	
Bjørnla	A Nordic multicenter survey of long-term bowel function after transanal	2	Eur	2	Co	Pro	Co
nd K, et	endorectal pull-through in 200 patients with rectosigmoid Hirschsprung disease	ō	ope	ō	mpa	spe	hort
al.	chaorectal pair through in 200 patients with rectosigniola thristispiang alsease	1	Opc	ő	rativ	ctiv	11011
ui.		7		"	e	e	
Bradno	Hirschsprung's disease in the UK and Ireland: Incidence and anomalies	2	Eur	3	Obs	Ret	Co
ck T, et	This one pranty of allocated in the ork and molaria. Indicates and anomalies	0	ope	0	erva	ros	hort
al.		1	OPC	5	tion	pec	11011
		7			al	tive	
Cheng	Pathologically assessed grade of Hirschsprung-associated enterocolitis in	2	Asia	8	Co	Ret	Co
S, et al.	resected colon in children with Hirschsprung's disease predicts postoperative	0	1.0.0	Ō	mpa	ros	hort
-,	bowel function	1			rativ	pec	
		7	ľ		е	tive	
Collins	Quality of life outcomes in children with Hirschsprung disease	2	Oce	6	Obs	Ret	Co
L, et al.		0	ania	0	erva	ros	hort
,		1			tion	pec	
		7			al	tive	
Ghosh	Transition zone pull-through in Hirschsprung's disease: a tertiary hospital	2	Oce	5	Obs	Ret	Co
D, et al.	experience	0	ania	0	erva	ros	hort
		1			tion	pec	
		7			al	tive	
Granéli	Diagnosis, Symptoms, and Outcomes of Hirschsprung's Disease from the	2	Eur	5	Co	Ret	Co
C, et al.	Perspective of Gender	0	ope	1	mpa	ros	hort
		1			rativ	pec	
Haasani	Treatment and Deticut Departed Outcome in Children with Hissohomsung	7	E.w	-	e Oha	tive	-
Hasseri us J, et	Treatment and Patient Reported Outcome in Children with Hirschsprung Disease and Concomitant Congenital Heart Disease	2	Eur	5 3	Obs	Ret	Co
al.	Disease and Concomitant Congenital Heart Disease	0	ope	3	erva tion	ros	hort
ai.		7			al	pec	
Kyrklun	Social Morbidity in Relation to Bowel Functional Outcomes and Quality of Life	2	Eur	6	Obs	Ret	Co
d K, et	in Anorectal Malformations and Hirschsprung's Disease	0	ope	1	erva	ros	hort
al.	Sola manormanono and misonoprung o biscusc	1	SPC	-	tion	pec	
۵		7			al	tive	
Li S, et	Clinical effects of ascending colon patching ileorectal heart-shaped	2	Asia	1	Obs	Pro	Co
al.	anastomosis on total colonic aganglionosis	0		5	erva	spe	hort
-		1			tion	ctiv	
		7			al	е	
	Laparoscopic-assisted endorectal pull-through for Hirschsprung's disease. A	2	Asia	2	Obs	Ret	Co
Li X, et		١.		2	erva	ros	hort
Li X, et al.	retrospective study	0				pec	
	retrospective study	1			tion		1
al.		1 7			al	tive	
al. Löf	Mortality in Swedish patients with Hirschsprung disease	1 7 2	Eur	7	al Obs	tive Pro	Со
al. Löf Granstr		1 7 2 0	Eur ope	3	al Obs erva	Pro spe	Co hort
Löf Granstr öm A,		1 7 2 0 1	1		al Obs erva tion	Pro spe ctiv	1
Löf Granstr öm A, et al.	Mortality in Swedish patients with Hirschsprung disease	1 7 2 0 1 7	ope	3 9	al Obs erva tion al	Pro spe ctiv e	hort
Löf Granstr öm A, et al. Lu C,	Mortality in Swedish patients with Hirschsprung disease  Single-stage transanal endorectal pull-through procedure for correction of	1 7 2 0 1 7	1	3 9	al Obs erva tion al Co	Pro spe ctiv e Pro	hort
Löf Granstr öm A, et al.	Mortality in Swedish patients with Hirschsprung disease	1 7 2 0 1 7 2 0	ope	3 9 4 1	al Obs erva tion al Co mpa	Pro spe ctiv e Pro spe	hort
Löf Granstr öm A, et al. Lu C,	Mortality in Swedish patients with Hirschsprung disease  Single-stage transanal endorectal pull-through procedure for correction of	1 7 2 0 1 7 2 0 1	ope	3 9	al Obs erva tion al Co mpa rativ	Pro spe ctiv e Pro spe ctiv	hort
Löf Granstr öm A, et al. Lu C,	Mortality in Swedish patients with Hirschsprung disease  Single-stage transanal endorectal pull-through procedure for correction of	1 7 2 0 1 7 2 0	ope	3 9 4 1	al Obs erva tion al Co mpa	Pro spe ctiv e Pro spe	hort

G, et al.	Aganglionosis: Outcome Assessed by Fecal Continence Evaluation	0 1 7		1	erva tion al	spe ctiv e	hort
Neuvon en N, et al.	Lower urinary tract symptoms and sexual functions after endorectal pull-through for Hirschsprung disease: controlled long-term outcomes	2 0 1 7	Eur ope	5 9	Co mpa rativ e	Ret ros pec tive	Co hort
Neuvon en M, et al.	Bowel function and quality of life after transanal endorectal pull-through for Hirschsprung's disease	2 0 1 7	Eur ope	7 9	Obs erva tion al	Ret ros pec tive	Co hort
Onishi S, et al.	The bowel function and quality of life of Hirschsprung disease patients who have reached 18 years of age or older – the long-term outcomes after undergoing the transabdominal soave procedure	2 0 1 7	Asia	1 6	Obs erva tion al	Pro spe ctiv e	Co hort
Sosno wska P, et al.	Definitive surgery for Hirschsprung's disease under 4 months of age is associated with long-term complications: A cohort study	2 0 1 7	Eur ope	3	Obs erva tion al	Ret ros pec tive	Co hort
Stenstr öm P, et al.	Patient-reported Swedish nationwide outcomes of children and adolescents with total colonic aganglionosis	2 0 1 7	Eur ope	7	Obs erva tion al	Ret ros pec tive	Co hort
T. Taguch i T, et al.	Current status of Hirschsprung's disease: based on a nationwide survey of Japan	2 0 1 7	Asia	1 0 8 7	Obs erva tion al	Ret ros pec tive	Co hort
Tannuri A, et al.	Long-term results of the Duhamel technique are superior to those of the transanal pullthrough: A study of fecal continence and quality of life	2 0 1 7	Sout h- Ame rica	4	Obs erva tion al	Ret ros pec tive	Co hort
Thakka r H, et al.	Functional outcomes in Hirschsprung disease: A single institution's 12-year experience	2 0 1 7	Eur ope	7 2	Obs erva tion al	Ret ros pec tive	Co hort
Tian Y, et al.	Difference of efficacy between Laparoscopic Modified Soave operation and Open Radical Resection in the treatment of Hirschsprung's disease	2 0 1 7	Asia	2 1 6	Co mpa rativ e	Pro spe ctiv e	Tria I
Yan J, et al.	Comparison of transcolostomy single-incision laparoscopic and open procedures in secondary operations for Hirschsprung's disease	2 0 1 7	Asia	3 7	Co mpa rativ e	Ret ros pec tive	Co hort
Zhang J, et al.	A 5-year follow-up study of neonates with Hirschsprung's disease undergoing transanal Soave or Swenson surgery	2 0 1 7	Asia	2 9	Co mpa rativ e	Ret ros pec tive	Co hort
Zhang X, et al.	Laparoscopic Duhamel Procedure with Ex-Anal Rectal Transection for Right-Sided Hirschsprung's Disease	2 0 1 7	Asia	1 8	Co mpa rativ e	Ret ros pec tive	Co hort
Hao Y, et al.	Application of a modified reflux enema method with indwelled anal canal in infants with long-segment Hirschsprung's disease	2 0 1 8	Asia	1 0 4	Co mpa rativ e	Ret ros pec tive	Tria I
Amin R, et al.	Long-term Quality of Life in Neonatal Surgical Disease	2 0 1 8	Nort h- Ame rica	4 6	Obs erva tion al	Ret ros pec tive	Co hort
Anders on J, et al.	Epidemiology of Hirschsprung disease in California from 1995 to 2013	2 0 1 8	Nort h- Ame rica	2 4 6 4	Obs erva tion al	Ret ros pec tive	Co hort
Chung P, et al.	Are all patients with short segment Hirschsprung's disease equal? A retrospective multicenter study	2 0 1 8	Asia	4 5	Obs erva tion al	Ret ros pec tive	Co hort
Frykma n P, et	Critical evaluation of the Hirschsprung-associated enterocolitis (HAEC) score: A multicenter study of 116 children with Hirschsprung disease	2 0	Inter	1	Obs erva	Pro spe	Co hort

al.		1	inen	6	tion	ctiv	
a.		8	tal	J	al	e	
Granstr	Increased Risk of Inflammatory Bowel Disease in a Population-based Cohort	2	Eur	7	Obs	Ret	Co
öm A,	Study of Patients with Hirschsprung Disease	0	ope	3	erva	ros	hort
et al.		1 8		9	tion al	pec tive	
Gunadi	Outcomes in patients with Hirschsprung disease following definitive surgery	2	Asia	6	Obs	Pro	Co
, et al.	Outcomes in patients with importage disease fellowing definitive surgery	0	71010	7	erva	spe	hort
,		1			tion	ctiv	
		8			al	е	
Hashim	Modified Duhamel pull through procedure in patients with Hirschsprung's	2	Asia	7 5	Obs	Pro	Co
I, et al.	disease	0		Э	erva tion	spe ctiv	hort
		8			al	e	
Huang	Prevalence, Risk Factors, and Prognosis of Postoperative Complications after	2	Asia	1	Obs	Pro	Co
W, et	Surgery for Hirschsprung Disease	0		8	erva	spe	hort
al.		1		1	tion	ctiv	
Jiao C,	A Long-Term Follow-Up of a New Surgery Method: Laparoscope-Assisted	8	Asia	1	al Co	e Ret	Co
et al.	Heart-Shaped Anastomosis for Hirschsprung's Disease	0	Asia	1	mpa	ros	hort
		1		0	rativ	pec	
		8			е	tive	
Li T, et	Long term outcomes for neonates of Hirschsprung's disease undergoing	2	Asia	7	Co	Ret	Co
al.	transanal Swenson or Duhamel pull-through by a 5 year follow-up study	0		9	mpa rativ	ros	hort
		8			e	tive	
Miyano	Hirschsprung's disease in the laparoscopic transanal pull-through era:	2	Asia	1	Obs	Pro	Co
G, et	implications of age at surgery and technical aspects	0		0	erva	spe	hort
al.		1		6	tion	ctiv	
NI-I- C	Access to large Manager to a California de C	8	<b>A</b> -:-	4	al	e	0-
Nah S,	Anorectal malformation & Hirschsprung's disease: A cross-sectional comparison of quality of life and bowel function to healthy controls	2	Asia	4 4	Co	Ret	Co hort
et al.	comparison of quality of life and bower function to nearity controls	1		4	mpa rativ	ros pec	Hort
		8			е	tive	
Palazó	Bilateral hydrosalpinx in patients with Hirschsprung's disease	2	Eur	1	Co	Ret	Co
n P, et		0	ope	7	mpa	ros	hort
al.		1 8			rativ	pec	
Parahit	Comparison of Hirschsprung-associated enterocolitis following Soave and	2	Asia	1	e Co	tive Ret	Co
a I, et	Duhamel procedures	0	71514	Ō	mpa	ros	hort
al.		1		0	rativ	pec	
		8			е	tive	
Pathak	Hirschsprung's disease and neonatal intestinal obstruction: Where does it lie in	2	Asia	1	Со	Ret	Co
M, et al.	the spectrum?	0		7	mpa rativ	ros pec	hort
ai.		8			e	tive	
Roorda	Long-term outcome and quality of life in patients with total colonic	2	Eur	5	Obs	Ret	Co
D, et al.	aganglionosis in the netherlands	0	ope	1	erva	ros	hort
		1			tion	pec	
Sood	The long-term quality of life outcomes in adolescents with Hirschsprung	8	Oce	8	al Obs	tive Pro	Со
S, et al.	disease	0	ania	3	erva	spe	hort
-,		1			tion	ctiv	
		8			al	е	
Tran V,	Interest of anorectal manometry during long-term follow-up of patients operated	2	Eur	5	Co	Ret	Co
et al.	on for Hirschsprung's disease	0	ope	3	mpa rativ	ros pec	hort
		8			e	tive	
Tran V,	Long-Term Outcomes and Quality of Life in Patients after Soave Pull-Through	2	Eur	5	Co	Ret	Co
et al.	Operation for Hirschsprung's Disease: An Observational Retrospective Study	0	ope	3	mpa	ros	hort
		1			rativ	pec	
Urla C,	Surgical treatment of children with total colonic aganglionosis: functional and	8	Eur	1	e Obs	tive Ret	Co
et al.	metabolic long-term outcome	0	ope	1	erva	ros	hort
		1		_	tion	pec	
		8			al	tive	
Veras	Impaired growth outcomes in children with congenital colorectal diseases	2	Nort	7	Obs	Ret	Co
L, et al.		0	h- Ame	1	erva tion	ros	hort
		1	AIIIC		เเปป	pec	1

		8	rica		al	tivo	
Widyas	Functional outcomes in Hirschsprung disease patients after transabdominal	2	rica Asia	5	Co	tive Ret	Co
ari A, et	Soave and Duhamel procedures	ő	Asia	3	mpa	ros	hort
al.	Source and Burnamor procedures	1			rativ	pec	
		8			е	tive	
Xi Z, et	Long-term complications of modified soave radical correction in the treatment	2	Asia	5	Co	Ret	Co
al.	of Hirschsprung's disease and its influences on life quality	0		0	mpa	ros	hort
		1			rativ	pec	
		8			е	tive	
Yokota	Single-stage laparoscopic transanal pull-through modified Swenson procedure	2	Asia	4	Co	Ret	Co
K, et al.	without leaving a muscular cuff for short- and long-type Hirschsprung disease:	0		3	mpa	ros	hort
	a comparative study	8			rativ e	pec tive	
Zhang	Laparoscopic-assisted Duhamel procedure with ex-anal rectal transection for	2	Asia	2	Co	Pro	Co
X, et al.	total colonic aganglionosis	0	71014	3	mpa	spe	hort
,		1			rativ	ctiv	
		8			е	е	
Zheng	Transanal endorectal stepwise gradient muscular cuff cutting pull-through	2	Asia	1	Co	Ret	Co
Z, et al.	method: Technique refinements and comparison with laparoscopy-assisted	0		7	mpa	ros	hort
	procedures	1		2	rativ	pec	
A series 1		8	<b></b>	_	e	tive	0-
Amin L, et al.	Swedish national population-based study shows an increased risk of depression among patients with Hirschsprung disease	2	Eur	7	Co mpa	Pro spe	Co hort
ci ai.	acpression among patients with imscrisplang disease	1	ope	9	rativ	ctiv	11011
		9			e	e	
Ashjaei	Early oral feeding versus traditional feeding after transanal endorectal pull-	2	Asia	3	Co	Pro	Tria
B, et al.	through procedure in Hirschsprung's disease	0		3	mpa	spe	1
		1			rativ	ctiv	
		9			е	е	
Askarp	Complications after transabdominal Soave's procedure in children with	2	Asia	1	Obs	Pro	Co
our S,	Hirschsprung's disease	0		6	erva	spe	hort
et al.		9		0	tion al	ctiv	
Chung	Risk factors for the development of post-operative enterocolitis in short	2	Asia	9	Obs	e Ret	Co
P, et al.	segment Hirschsprung's disease	ō	Asia	6	erva	ros	hort
, , , , ,	ooginisht i moonop ang o anooaco	1			tion	pec	
		9			al	tive	
Dingem	Urinary Outcomes in Patients with Down's Syndrome and Hirschsprung's	2	Eur	1	Co	Ret	Co
ans A,	Disease	0	ope	0	mpa	ros	hort
et al.		1		4	rativ	pec	
Duisai	Language Outcome of Hisphanium Diocess Immedian Ouelibraf Life and	9	E	_	e Oha	tive	-
Drissi F, et al.	Long-term Outcome of Hirschsprung Disease: Impact on Quality of Life and Social Condition at Adult Age	2	Eur ope	3 4	Obs erva	Pro spe	Co hort
i, et al.	Social Condition at Addit Age	1	Ope	~	tion	ctiv	11011
		9			al	e	
El Ç, et	A significant cause of constipation and growth retardation: Hirschsprung's	2	Eur	1	Obs	Ret	Co
al.	disease	0	asia	9	erva	ros	hort
		1			tion	pec	
		9	<u> </u>		al	tive	$\vdash$
Freedm	Delay in operation for Hirschsprung Disease is associated with decreased length of stay: a 5-Year NSOIP-Peds analysis	2	Nort	2	Co	Ret	Co
an- Weiss	rengin of stay, a 5-year insqir-reus analysis	0	h- Ame	8	mpa rativ	ros pec	hort
M, et		9	rica		e	tive	
al.		-					
Fusaro	Autologous intestinal reconstructive surgery in the management of total	2	Eur	1	Obs	Ret	Co
F, et al.	intestinal aganglionosis	0	ope	4	erva	ros	hort
		1			tion	pec	
Oh	Forth and long town complications following transport	9	Λ =:	_	al	tive	
Ghorba	Early and long-term complications following transanal pull through Soave	2	Asia	5	Obs	Ret	Ca
npour M, et	technique in infants with Hirschsprung's disease	0		5	erva tion	ros pec	se seri
al.		9			al	tive	es
Granstr	No increased risk of attention deficit hyperactivity disorders in patients with	2	Eur	7	Co	Ret	Co
öm A,	Hirschsprung disease	ō	ope	3	mpa	ros	hort
et al.		1		9	rativ	pec	
		9			е	tive	
Gupta		1 2	Asia	3	Obs	Pro	Ca
	Experience with the Redo Pull-Through for Hirschsprung's Disease	2	Asia			1	
D, et al.	Experience with the Redo Pull-1 nrough for Hirschsprung's Disease	0 1	Asia	2	erva tion	spe ctiv	se seri

		9			al	е	es
Gustafs	Controlled outcome of Hirschsprung's disease beyond adolescence: a single	2	Eur	1	Co	Ret	Co
on E, et	center experience	0	ope	2	mpa	ros	hort
al.		1	-	3	rativ	pec	
		9			е	tive	
Han J,	Why Do the Patients with Hirschsprung Disease Get Redo Pull-Through	2	Asia	6	Obs	Ret	Co
et al.	Operation?	0		5	erva	ros	hort
		1		7	tion	pec	
I I o alles so	Children with Hissahammungle Disease and Construction with Constitute	9	F	_	al	tive	-
Hedbys	Children with Hirschsprung's Disease and Syndromes with Cognitive Dysfunction: Manifestations, Treatment, and Outcomes	2	Eur	6 3	Obs	Ret	Co
J, et al.	Dysiunction. Mainestations, Treatment, and Outcomes	1	ope	3	erva tion	ros pec	hort
		9			al	tive	
Hoff N,	Classification of short-term complications after transanal endorectal pullthrough	2	Eur	6	Obs	Ret	Co
et al.	for Hirschsprung's disease using the Clavien–Dindo-grading system	0	ope	9	erva	ros	hort
		1	· .		tion	pec	
		9			al	tive	
lacusso	Minimally invasive techniques for Hirschsprung's disease	2	Eur	1	Co	Ret	Co
C, et al.		0	ope	4	mpa	ros	hort
		1		5	rativ	pec	
liona	Language Dada Dull Through for Hiraghanning Diagona Dua to Innoviation	9	Agia	0	e Obo	tive	C0
Jiang M, et	Laparoscopic Redo Pull-Through for Hirschsprung Disease Due to Innervation Disorders	2	Asia	8	Obs erva	Ret	Co hort
al.	Distriucis	1		6	tion	pec	11011
a.		9		"	al	tive	
Jiao C,	Results of rectoanal manometry after a novel laparoscopic technique:	2	Asia	8	Obs	Ret	Со
et al.	laparoscope-assisted heart-shaped anastomosis for Hirschsprung's disease	0		0	erva	ros	hort
		1			tion	pec	
		9			al?	tive	
Le-	Factors influencing the incidence of Hirschsprung associated enterocolitis	2	Nort	1	Co	Pro	Co
Nguyen	(HAEC)	0	h-	7	mpa	spe	hort
A, et al.		1	Ame	1	rativ	ctiv	
Lauta	Newsorther detices and ded April Later architecturic Detailing at Table Later time in	9	rica	4	e	e	0-
Louis- Borrion	Neurostimulation-guided Anal Intrasphincteric Botulinum Toxin Injection in	0	Eur	1 5	Obs	Ret	Co
e C, et	Children With Hirschsprung Disease	1	ope	3	erva tion	ros pec	hort
al.		9			al	tive	
Meinds	Long-term functional outcomes and quality of life in patients with	2	Eur	8	Co	Pro	Ca
R, et al.	Hirschsprung's disease	0	ope	3	mpa	spe	se-
		1	·	0	rativ	ctiv	con
		9			е	е	trol
Nakam	Treatment of classic-type Hirschsprung's disease: rectoplasty with posterior	2	Asia	6	Co	Pro	Co
ura M,	triangular colonic flap versus transanal endorectal pull-through with rectoanal	0		4	mpa	spe	hort
et al.	myotomy	9			rativ	ctiv	
Matarai	Management of Hirschsprung disease in Australia and New Zealand: a survey	2	Oce	-	e Obs	e Pro	Co
Nataraj a R, et	of the Australian and New Zealand Association of Paediatric Surgeons	0	ania	_	erva	spe	hort
al.	(ANZAPS)	1	ana		tion	ctiv	11011
\		9			al	e	
Obata	The outcomes of transanal endorectal pull-through for Hirschsprung's disease	2	Asia	1	Co	Ret	Co
S, et al.	according to the mucosectomy-commencing points: A study based on the	0		0	mpa	ros	hort
	results of a nationwide survey in Japan	1		8	rativ	pec	
		9		7	е	tive	
Obata	Nationwide survey of outcome in patients with extensive aganglionosis in	2	Asia	1	Obs	Ret	Co
S, et al.	Japan	0		0	erva	ros	hort
		9		8	tion al	pec tive	
Pini	Hirschsprung disease and Down syndrome: From the reappraisal of risk factors	2	Eur	3	Obs	Pro	Co
Prato	to the impact of surgery	ō	ope	8	erva	spe	hort
A, et al.		1		5	tion	ctiv	
		9			al	е	
Purcell	Characteristics and outcomes in paediatric patients presenting with congenital	2	Afric	8	Obs	Ret	Co
L, et al.	colorectal diseases in sub-Saharan Africa	0	а	2	erva	ros	hort
		1			tion	pec	
0-1- 5	The relationship of a classic with a sign of the control of the co	9	NI.		al	tive	$\vdash$
Sola R,	The relationship of eosinophilia with outcomes of Hirschsprung disease in	2	Nort	1	Co	Ret	Co
et al.	children	0	h- Ame	0	mpa rativ	ros pec	hort
		9	rica	"	e	tive	
			noa			uve	

Wang	Three-Dimensional Versus Two-Dimensional Laparoscopic-Assisted Transanal	2	Asia	8	Co	Ret	Co
Y, et al.	Pull-Through for Hirschsprung's Disease in Children: Preliminary Results of a	0		0	mpa	ros	hort
	Prospective Cohort Study in a Tertiary Hospital	1			rativ	pec	
V. D	Tanana kili ada antara da marifa di limada manda di antara di la da di la da di la da di la da da di la da da di la da da di la da	9	A = : =	_	e	tive	0-
Xu P,	Transumbilical enterostomy for Hirschsprung's disease with a twostage laparoscopy-assisted pull-through procedure	2	Asia	5	Co	Ret	Co
et al.	aparoscopy-assisted pull-trirough procedure	0		3	mpa	ros	hort
		9			rativ e	pec tive	
Youn J,	Botulinum toxin injection for internal anal sphincter achalasia after pull-through	2	Asia	1	Obs	Ret	Co
et al.	surgery in Hirschsprung disease	0	Asia	5	erva	ros	hort
Ct ai.	Surgery in this one pruning discuse	1			tion	pec	11011
		9			al	tive	
Zhu T,	Optimal time for single-stage pull-through colectomy in infants with short-	2	Asia	1	Co	Pro	Co
et al.	segment Hirschsprung disease	0		9	mpa	spe	hort
		1		8	rativ	ctiv	
		9			е	е	
Aliev	A comparative study of the surgical procedures to treat Hirschsprung's disease	2	Asia	1	Co	Ret	Co
M, et	in children	0		3	mpa	ros	hort
al.		2		8	rativ	pec	
		0		-	е	tive	_
Bawazi	Laparoscopic-assisted transanal pull-through in Hirschsprung's disease: Does	2	Asia	7	Co	Ret	Co
rO	laparoscopic dissection minimize anal overstretching?	0		4	mpa	ros	hort
		2			rativ	pec tive	
Brooks	Resection margin histology may predict intermediate-term outcomes in children	2	Nort	4	e Co	Ret	Co
L, et al.	with rectosigmoid Hirschsprung disease	0	h-	5	mpa	ros	hort
L, et al.	with rectosignoid rinscrispiding disease	2	Ame	]	rativ	pec	11011
		0	rica		e	tive	
Dai Y,	Parental Self-efficacy and Health-related Outcomes Among Children with	2	Asia	8	Obs	Ret	Co
et al.	Hirschsprung Disease: A Cross-sectional Study	0	7 10.00	4	erva	ros	hort
		2			tion	pec	
		0			al	tive	
Dariel	Analysis of enteric nervous system and intestinal epithelial barrier to predict	2	Eur	1	Obs	Ret	Co
A, et al.	complications in Hirschsprung's disease	0	ope	8	erva	ros	hort
		2			tion	pec	
		0			al	tive	
Fang	Laparoscopic Soave procedure for long-segment Hirschsprung's disease -	2	Asia	3	Obs	Ret	Co
Y, et al.	single-center experience	0		1	erva	ros	hort
		2			tion	pec	
Fosby	Bowel function after transanal endorectal pull-through for Hirschsprung disease	2	Eur	5	al Obs	tive Ret	Co
M, et	- does outcome improve over time?	0	ope	0	erva	ros	hort
al.	- does outcome improve over time:	2	Ope	"	tion	pec	11011
Ci.		0			al	tive	
Gabriel	Long-term growth outcomes in children with Hirschsprung disease after	2	Asia	2	Co	Pro	Co
a G, et	definitive surgery: A cross-sectional study	0		1	mpa	spe	hort
al.		2			rativ	ctiv	
		0			е	е	
Giuliani	Outcomes of Primary versus Multiple-Staged Repair in Hirschsprung's Disease	2	Eur	1	Co	Ret	Co
S, et al.	in England	0	ope	3	mpa	ros	hort
		2		3	rativ	pec	
C "	Country systematics in Lincolners were allowed as the second of the seco	0	Δ-:	3	e	tive	
Gunadi	Growth outcomes in Hirschsprung's disease patients following pull-through	2	Asia	6	Co	Pro	Co
, et al.		0 2		4	mpa	spe ctiv	hort
		0			rativ e	e	
Gunadi	Postoperative enterocolitis assessment using two different cut-off values in the	2	Asia	8	Co	Pro	Co
, et al.	HAEC score in Hirschsprung patients undergoing Duhamel and Soave pull-	0	, Gia	3	mpa	spe	hort
, 5. a	through	2		~	rativ	ctiv	
	, and the second	0			e	e	
Hallera	Does Hirschsprung-Associated Enterocolitis Differ in Children With and Without	2	Nort	8	Co	Pro	Co
	, ,	0	h-	6	mpa	spe	hort
n D, et	Down Syndrome?	0			· · ·		ı l
n D, et al.	Down Syndrome?	2	Ame		rativ	ctiv	
					е	e ctiv	
al. Hossei	Mechanical Bowel Preparation versus No Preparation in Duhamel Procedure in	2 0 2	Ame	8	e Co	e Ret	Tria
al. Hossei npour		2 0 2 0	Ame rica	8 0	e Co mpa	e Ret ros	Tria I
al.  Hossei npour M, et	Mechanical Bowel Preparation versus No Preparation in Duhamel Procedure in	2 0 2 0 2	Ame rica	l	e Co mpa rativ	Ret ros pec	Tria I
al. Hossei npour	Mechanical Bowel Preparation versus No Preparation in Duhamel Procedure in	2 0 2 0	Ame rica	l	e Co mpa	e Ret ros	Tria I

D et el	array or an inquitable complication?		one	4	0510	roo	hort
D, et al.	error or an inevitable complication?	0	ope	4	erva	ros	hort
		2			tion	pec	
1/	The effect of coultible in linear college to be a decided as the college to the c		N.It	4	al	tive	-
Kasten	The effect of multidisciplinary colorectal center development on short-term	2	Nort	1	Obs	Pro	Co
berg Z,	hospital readmissions for patients with anorectal malformations or	0	h-	3	erva	spe	hort
et al.	Hirschsprung disease	2	Ame	1	tion	ctiv	
		0	rica		al	е	
Meng	Long-term outcomes of single-incision laparoscopic technique in Soave	2	Asia	2	Obs	Ret	Co
X, et al.	procedure compared with heart-shaped anastomosis for Hirschsprung disease	0		0	erva	ros	hort
		2		4	tion	pec	
		0			al	tive	
Mille E,	Quality of life and neuropsychological development at school age in	2	Eur	1	Co	Ret	Ca
et al.	Hirschsprung's disease	0	ope	5	mpa	ros	se-
or a	Timeshe braing a anasaas	2	opo		rativ	pec	con
		0			е	tive	trol
Napar	Classical Swenson abdomino-perineal pull through technique in the treatment	2	Asia	5	Obs	Ret	Co
Napai N, et al.	of Hirschsprung's disease-4 years experience	0	Asia	0	erva	ros	hort
iv, et al.	of miscrisprurig's disease-4 years experience			0			HOIL
		2			tion	pec	
		0		_	al	tive	-
Neuvon	A population-based, complete follow-up of 146 consecutive patients after	2	Eur	1	Obs	Ret	Со
en M,	transanal mucosectomy for Hirschsprung disease	0	ope	4	erva	ros	hort
et al.		2		6	tion	pec	
		0			al	tive	
Oh C,	The Patients with Hirschsprung's Disease Who Underwent Pull-Through at Age	2	Asia	3	Obs	Ret	Co
et al.	Less than 1 Year: Longitudinal Bowel Function	0		9	erva	ros	hort
		2		6	tion	pec	
		0			al	tive	
Peters	Modified Duhamel's Two-Staged Procedure for Hirschsprung's Disease:	2	Asia	6	Obs	Pro	Co
N, et al.	Further Modifications for Improved Outcomes	0	71014	9	erva	spe	hort
iv, et al.	Turtilet Woullications for improved Outcomes	2		٦	tion	ctiv	Hort
D: :		0	_	_	al	e	
Pini	Totally robotic soave pull-through procedure for Hirschsprung's disease:	2	Eur	1	Obs	Ret	Ca
Prato	lessons learned from 11 consecutive pediatric patients	0	ope	1	erva	ros	se
A, et al.		2			tion	pec	seri
		0			al	tive	es
Pini	Minimally Invasive Redo Pull-Throughs in Hirschsprung Disease	2	Eur	1	Obs	Ret	Ca
Prato		0	ope	6	erva	ros	se
A, et al.		2	- 1.		tion	pec	seri
.,		0			al	tive	es
Pruitt L,	Impact of consolidation of cases on post-operative outcomes for index pediatric	2	Nort	2	Obs	Ret	Co
et al.	surgery cases	0	h-	o	erva	ros	hort
et al.	surgery cases						HOIL
		2	Ame	3	tion	pec	
		0	rica	0	al	tive	<u> </u>
Pruitt L,	Hirschsprung-associated enterocolitis in children treated at US children's	2	Nort	2	Obs	Ret	Co
et al.	hospitals	0	h-	0	erva	ros	hort
		2	Ame	3	tion	pec	
		0	rica	0	al	tive	
Quiroz	Pull-through procedure in children with Hirschsprung disease: A nationwide	2	Nort	3	Obs	Ret	Co
H, et al.	analysis on postoperative outcomes	0	h-	6	erva	ros	hort
		2	Ame	3	tion	pec	
		0	rica	5	al	tive	
Saad	Histopathological perspective of the pulled-through colon in Hirschsprung	2	Afric	3	Obs	Ret	Co
S, et al.	disease: Impact on clinical outcome	0	a	5	erva	ros	hort
S, et al.	disease. Impact on clinical outcome		a	3			Hort
		2			tion	pec	
Ca	Ovelle, of life of notionts with Hissohom and discount of the Dubance Life	0	A # ! =	1	al	tive	-
Saysoo	Quality of life of patients with Hirschsprung disease after Duhamel and Soave	2	Asia	1	Co	Ret	Co
M, et	pull-through procedures: A mixed-methods sequential explanatory cohort study	0		1	mpa	ros	hort
al.		2		ľ	rativ	pec	
		0			е	tive	
Schlun	A national analysis of operative treatment of adult patients with Hirschsprung's	2	Nort	3	Co	Pro	Co
d D, et	disease	0	h-	2	mpa	spe	hort
al.		2	Ame		rativ	ctiv	
		0	rica		е	е	
Stenstr	Total colonic aganglionosis: multicentre study of surgical treatment and patient-	2	Eur	1	Co	Ret	Со
öm P,	reported outcomes up to adulthood	0	ope	1	mpa	ros	hort
et al.	Toportou outcomes up to addititioud	2	Ope	6	rativ	pec	11011
or an				"			
Cust-:-	Investigat annual and the characteristic control of the control of	0	Nicot	_	e	tive	-
	Inpatient management of Hirschsprung's associated enterocolitis treatment: the	2	Nort	2	Co	Pro	Co
Svetan off W,	benefits of standardized care	0	h-	7	mpa	spe	hort

et al.		2	Ame		rativ	ctiv	
01 0		0	rica		е	е	
Taghav	Contemporary management of Hirschsprung disease in New Zealand	2	Oce	2	Obs	Pro	Co
i K, et		0	ania	4	erva	spe	hort
al.		2		6	tion	ctiv	
Tang J,	Application of enhanced recovery after surgery during the perioperative period	2	Asia	1	al Co	e Pro	Tria
et al.	in infants with Hirschsprung's disease – A multi-center randomized clinical trial	0	Asia	4	mpa	spe	
ct ai.	in mans with miscrispring 3 disease – A main center randomized clinical than	2		8	rativ	ctiv	
		0			e	e	
Thakka	Variability of the transition zone length in Hirschsprung disease	2	Eur	4	Obs	Ret	Co
r H, et		0	ope	8	erva	ros	hort
al.		2			tion	pec	
		0	_		al	tive	
Vriesm	Outcomes after enterostomies in children with and without motility disorders: A	2	Eur	1	Obs	Ret	Co
an M, et al.	description and comparison of postoperative complications	0 2	ope	8	erva tion	ros	hort
et al.		0			al	pec tive	
Wall N,	Use of an enterocolitis triage and treatment protocol in children with	2	Nort	8	Obs	Pro	Co
et al.	Hirschsprung disease reduces hospital admissions	0	h-	7	erva	spe	hort
		2	Ame		tion	ctiv	
		0	rica		al	е	
Yan J,	Clinical Outcomes After Staged and Primary Laparotomy Soave Procedure for	2	Asia	3	Co	Ret	Co
et al.	Total Colonic Aganglionosis: a Single-Center Experience from 2007 to 2017	0		5	mpa	ros	hort
		2			rativ	pec	
		0		_	е	tive	
Zhang	Primary laparoscopic endorectal pull-through procedure with or without a	2	Asia	3	Co	Ret	Tria
X, et al.	postoperative rectal tube for Hirschsprung's disease: a multicenter perspective	0 2		8	mpa	ros	
	study	0		3	rativ e	pec tive	
Ali A, et	The Prevalence and Clinical Profile of Hirschsprung's Disease at a Tertiary	2	Asia	1	Obs	Ret	Co
al.	Hospital in Bahrain	0	7 10.00	8	erva	ros	hort
		2			tion	pec	
		1			al	tive	
Allin B,	Outcomes at five to eight years of age for children with Hirschsprung's disease	2	Eur	2	Obs	Ret	Co
et al.		0	ope	3	erva	ros	hort
		2		9	tion	pec	
Apfeld	Benchmarking utilization, length of stay, and complications following minimally	2	Nort	4	al Obs	tive Ret	Co
J, et al.	invasive repair of major congenital anomalies	0	h-	5	erva	ros	hort
o, cr ai.	invasive repair of major congernal anomalies	2	Ame	0	tion	pec	11011
		1	rica		al	tive	
Apfeld	Relationships Between Hospital and Surgeon Operative Volumes and Surgical	2	Nort	1	Obs	Pro	Co
J, et al.	Outcomes in Hirschsprung's Disease	0	h-	2	erva	spe	hort
		2	Ame	6	tion	ctiv	
		1	rica	8	al	е	
Arafa	Laparoscopic-assisted transanal pull-through for Hirschsprung's children older	2	Afric	1	Obs	Ret	Ca
A, et al.	than 3 years: A case series	2	a	5	erva	ros	se seri
		1			tion al	pec tive	seri es
Ashjaei	What is the appropriate aganglionic bowel length on contrast enema for	2	Asia	4	Obs	Ret	Co
B, et al.	attempting single stage transanal endorectal pull-through in Hirschsprung	0		8	erva	ros	hort
,	disease?	2			tion	pec	
		1			al	tive	
Askarp	Oblique vs. Circular anastomosis in the children underwent Soave's pull-	2	Asia	7	Obs	Ret	Co
our S,	through surgery for the treatment of Hirschsprung's disease: which is best?	0		0	erva	ros	hort
et al.		2			tion	pec	
Beltma	Risk factors for short-term complications graded by Clavien-Dindo after	2	Eur	1	al Obs	tive	<del>   </del>
n L, et	transanal endorectal pull-through in patients with Hirschsprung disease	0	Eur ope	0	erva	Ret ros	Co hort
al.	transana endorecta pun unough in panents with i inscrispiting disease	2	ope	6	tion	pec	11011
···		1			al	tive	
Bogusz	Laparoscopic histological mapping for the determination of the length of	2	Eur	1	Obs	Ret	Co
B, et al.	aganglionic segment in children with Hirschsprung disease	0	ope	4	erva	ros	hort
		2			tion	pec	
		1			al	tive	igsquare
Byströ	Evaluation of Bowel Function, Urinary Tract Function, and Quality of Life after	2	Eur	3	Co	Ret	Ca
m C, et	Transanal Endorectal Pull-Through Surgery for Hirschsprung's Disease	0	ope	0	mpa	ros	se-
al.		2	1	l	rativ	pec	con

		1			е	tive	trol
Chan	Long-Term Results of One-Stage Laparoscopic-Assisted Endorectal Pull-	2	Asia	4	Obs	Ret	Co
K, et al.	Through for Rectosigmoid Hirschsprung's Disease in Patients Aged above 5	0	7 10101	1	erva	ros	hort
,	Years	2			tion	pec	
		1			al	tive	
Chen	Laparoscopic vs. Transabdominal Treatment for Overflow Fecal Incontinence	2	Asia	3	Obs	Pro	Co
F, et al.	Due to Residual Aganglionosis or Transition Zone Pathology in Hirschsprung's	0		0	erva	spe	hort
	Disease Reoperation	2			tion	ctiv	
		1			al	е	
Davids	Outcomes in Hirschsprung's disease with coexisting learning disability	2	Eur	3	Co	Ret	Co
on J, et		0	ope	2	mpa	ros	hort
al.		2			rativ	pec	
Davids	Language and provided and patient removind automaca of History world Discord	1	F	1	e Co	tive	Co
on J, et	Long-term surgical and patient-reported outcomes of Hirschsprung's Disease	2	Eur ope	8	mpa	Pro	hort
al.		2	ope	6	rativ	spe ctiv	Hort
aı.		1		0	e	e	
Delgad	Robotic Soave pull-through procedure for Hirschsprung's disease in children	2	Nort	1	Obs	Pro	Co
0-	under 12-months: long-term outcomes	ō	h-	5	erva	spe	hort
Miguel	and 22 monard form datasened	2	Ame	,	tion	ctiv	
C, et al.		1	rica		al	е	
Gunadi	Functional outcomes of patients with short-segment Hirschsprung disease after	2	Asia	5	Obs	Pro	Co
, et al.	transanal endorectal pull-through	0		0	erva	spe	hort
		2			tion	ctiv	
		1			al	е	
Gunadi	Comparison of Two Different Cut-Off Values of Scoring System for Diagnosis	2	Asia	7	Obs	Ret	Co
, et al.	of Hirschsprung-Associated Enterocolitis After Transanal Endorectal Pull-	0		0	erva	ros	hort
	Through	2			tion	pec	
		1			al	tive	<u> </u>
Kasten	Perioperative and long-term functional outcomes of neonatal versus delayed	2	Nort	8	Obs	Ret	Co
berg Z,	primary endorectal pull-through for children with Hirschsprung disease: A	0	h-	2	erva	ros	hort
et al.	pediatric colorectal and pelvic learning consortium study	2	Ame		tion	pec	
Li O. ot	Cursical approach and functional autoema of rade null through for	1	rica	3	al	tive	Co
Li Q, et al.	Surgical approach and functional outcome of redo pull-through for postoperative complications in Hirschsprung's disease	2	Asia	6	Obs erva	Pro spe	hort
ai.	postoperative complications in i inscrispining s disease	2		U	tion	ctiv	Hort
		1			al	e	
Liang	Role of mechanical and oral antibiotic bowel preparation in children with	2	Asia	6	Obs	Ret	Co
Y, et al.	Hirschsprung's disease undergoing colostomy closure and pull-through	0		4	erva	ros	hort
		2			tion	pec	
		1			al	tive	
Lin Z,	Outcomes of preoperative anal dilatation for Hirschsprung disease	2	Asia	9	Co	Ret	Co
et al.		0		5	mpa	ros	hort
		2			rativ	pec	
		1			е	tive	
Liu Q,	Application of trinity new model home nursing in postoperative management of	2	Asia	8	Co	Ret	Co
et al.	children with Hirschsprung's disease	0		0	mpa	ros	hort
		2			rativ	pec	
Logona	Approximant of Quality of Life and Europiana Containing of Organization	1	Λc:-	-	e Oho	tive	-
Logana	Assessment of Quality of Life and Functional Outcomes of Operated Cases of Hirschsprung Disease in a Developing Country	2	Asia	8 6	Obs	Ret	Co
than A, et al.	mirocrisprung disease in a developing Country	2		١٥	erva tion	ros pec	hort
el al.		1			al	tive	
Min J,	Clinical predictors of readmission after surgery for Hirschsprung disease	2	Asia	1	Obs	Ret	Co
et al.	Similar predictors of redultinssion after surgery for this enspiring disease	0	Asia	6	erva	ros	hort
Ji an		2		2	tion	pec	
		1			al	tive	
Moham	Optimism for the Single-stage Transanal Swenson in Neonates	2	Afric	2	Obs	Pro	Co
ed W,	, , , , , , , , , , , , , , , , , , , ,	ō	a	3	erva	spe	hort
et al.		2			tion	ctiv	
		1		<u></u>	al	е	
Nguyen	Suspension sutures facilitate single-incision laparoscopic-assisted rectal pull-	2	Asia	4	Obs	Ret	Ca
L, et al.	through for Hirschsprung disease	0		0	erva	ros	se
		2			tion	pec	seri
		1			al	tive	es
Olivos	Current practice of rectal biopsies for the diagnosis of Hirschsprung's disease	2	Sout	0	Obs	Ret	Co
M, et	in Latin America: an international online survey	0	h-		erva	ros	hort
	•	_				I .	
al.	·	2	Ame rica		tion al	pec tive	

_							
Pecora	Factors Affecting Higher Readmission Rates and Costs in Pediatric Patients	2	Nort	3	Obs	Ret	Co
ro A, et	With Hirschsprung Disease	0	h-	3	erva	ros	hort
al.		2	Ame	4	tion	pec	
D	De de transport de como de la transport de la como de l	1	rica	5	al	tive	0-
Peng	Redo transanal soave pull through with or without assistance in Hirschsprung's	2	Asia	4	Obs	Ret	Co
C, et al.	disease: An experience in 46 patients	0		6	erva	ros	hort
		2			tion	pec	
Pini	Congenital anomalies of the kidney and urinary tract in a cohort of 280	2	Eur	2	al Obs	tive Ret	Co
Prato		0		8			
A, et al.	consecutive patients with Hirschsprung disease	2	ope	0	erva tion	ros	hort
A, et al.		1		U	al	pec tive	
Rentea	Impact of Botulinum Toxin on Hirschsprung-associated Enterocolitis After	2	Nort	1	Co	Ret	Co
Rentea R, et al.	Primary Pull-Through	0	h-	4	mpa	ros	hort
r, et al.	Filliary Full-Tillough	2	Ame	3	rativ	pec	Hort
		1	rica	9	e	tive	
Roorda	Intrasphincteric botulinum toxin injections for post-operative obstructive	2	Eur	1	Obs	Ret	Co
D, et al.	defecation problems in Hirschsprung disease: A retrospective observational	0	ope	3	erva	ros	hort
D, et al.	study	2	ope	1	tion	pec	11011
	Study	1			al	tive	
Roorda	Risk factors for enterocolitis in patients with Hirschsprung disease: A	2	Eur	1	Obs	Pro	Co
D, et al.	retrospective observational study	0	ope	4	erva	spe	hort
D, Ct al.	Teliospeelive observational study	2	Opc	6	tion	ctiv	11011
		1		١	al	e	
Sakurai	Predictive factors for the development of postoperative Hirschsprung-	2	Asia	3	Co	Ret	Co
T, et al.	associated enterocolitis in children operated during infancy	0	Asia	5	mpa	ros	hort
i, et ai.	associated enteroconds in children operated during initiality	2		٦	rativ	pec	11011
		1			e	tive	
Shanka	Long-term outcomes in children with Hirschsprung's disease and transition	2	Asia	1	Obs	Pro	Co
r G, et	zone bowel pull-through: impact of surgical techniques and role for	ō	/ Noice	1	erva	spe	hort
al.	conservative approach	2		-	tion	ctiv	11011
a.	ourservative approach	1			al	e	
Shojaei	Bioavailability of rectal acetaminophen in children following anorectal surgery	2	Asia	2	Co	Pro	Co
an R,	2 - Carramas my or rootal acceptant of march romaning and catalogs.	0	/ 10.00	0	mpa	spe	hort
et al.		2			rativ	ctiv	
		1			e	е	
Taylor	Comparison of Hirschsprung Disease Characteristics between Those with a	2	Nort	2	Co	Pro	Ca
M, et	History of Postoperative Enterocolitis and Those without: Results from the	ō	h-	9	mpa	spe	se-
al.	Pediatric Colorectal and Pelvic Learning Consortium	2	Ame	9	rativ	ctiv	con
	The state of the s	1	rica		e	e	trol
Yang J,	Colonoscopic Diagnosis of Postoperative Gastrointestinal Bleeding in Patients	2	Asia	2	Obs	Ret	Co
et al.	With Hirschsprung's Disease	0		4	erva	ros	hort
		2			tion	pec	
		1			al	tive	
Yuan	The Efficacy of Biofeedback Therapy for the Treatment of Fecal Incontinence	2	Asia	4	Obs	Ret	Co
Y, et al.	After Soave Procedure in Children for Hirschsprung's Disease	0		6	erva	ros	hort
, , ,		2			tion	pec	
		1			al	tive	

#### **SUPPLEMENTARY 3: Extracted baseline characteristics**

\*As several parameters could arguably be included into more than one category, categorization was determined through agreement between the first two authors. Furthermore, we arranged the parameters by topic, such as patient characteristics, comorbidities, primary treatment, to facilitate the comparison of variation in studied parameters among similar subjects. Underlined items were studied in more than 5% of included publications. The items indicated as 5% but not underlined were identified in 4.5% of the included publications.

- <sup>a</sup> Classic triad refers to the presence of delayed passage of meconium, bilious vomiting and abdominal distension.
- <sup>b</sup> Extent of aganglionosis refers to the histological level of transitional zone, namely rectal, sigmoid, rectosigmoid, distal descending colon.

#### **Patient characteristics**

Sex         176         88%           Birth weight         42         21%           Small for gestational age         1         -1%           Effinicity         18         9½           Gestational age         36         18½           Premature         21         11½           Mode of delivery         1         -11%           Normal vaginal delivery         1         -11%           Family history of HSCR         28         14½           Age at first symptom         2         1%           Age at first symptom         1         1%           Duration of symptoms         15         88           Duration of symptoms         2         1%           Age at field agnosis         34         17%           Weight at diagnosis         1         -1%           Diagnosis during neonatal period         8         4%           Age at first contact with pediatric surgeon         1         -1%           Age at surgery         132         66%           Surgery during neonatal period         8         4%           Age at redo surgery         4         2%           Veight at surgery         1         -1%		n=	%
Birth weight         42         21%           Small for gestational age         1         41%           Birth height         2         14%           Ethnicity         18         9%           Gestational age         36         18%           Fremature         21         11%           Mode of delivery         1         15%           Normal vaginal delivery         1         11%           Family history of HSCR         28         14%           Age at first symptom         2         13%           Age at first symptoms         15         8%           Age at Diopsy         4         2%           Age at diagnosis         34         17%           Diagnosis during neonatal period         8         4%           Age at first contact with pediatric surgeon         1         21%           Age at surgery         32         4%           Age at Instruction with pediatric surgeon         1         2%           Age at Instruction with pediatric surgeon         1         2%           Age at Instruction with pediatric surgeon         8         4%           Age at Ired osurgery         9         2         1           Age at Ired osurgery<	Sav		-
Small for gestational age         1         <1%			
Birth height         2         1%           Ethnicity         18         9%           Gestational age         36         18%           Fremature         21         11%           Mode of delivery         1         4%           Normal vaginal delivery         1         1.1%           Eamily history of HSCR         28         14%           Age at first symptom         2         1%           Age at tressenting symptom         15         89           Duration of symptoms         2         1%           Age at biposy         4         2%           Age at diagnosis         3         4.2%           Weight at diagnosis         1         4.1%           Weight at diagnosis         1         4.1%           Diagnosis during neonatal period         8         4%           Age at surgery         13         66%           Surgery during neonatal period         8         4%           Age at redo surgery         4         2%           Weight at surgery         1         1.1%           Age at at demission         2         1.1%           Marriage/Relationship status         4         2           Place of			
Ethnicity         18         9%           Gestational age         36         18%           Premature         21         11%           Mode of delivery         1         <1%			
Gestational age         36         18%           Premature         21         11%           Mode of delivery         1         <1%			
Premature         21         11%           Mode of delivery         1         <1%			
Mode of delivery         1         <1%			
Normal vaginal delivery         1         <1%			
Eamily history of HSCR         28         14%           Age at first symptom         2         1%           Age at presenting symptom         15         8%           Duration of symptoms         2         1%           Age at biopsy         4         2%           Age at diagnosis         34         17%           Weight at diagnosis         1         <1%			
Age at first symptom         2         1%           Age at presenting symptom         15         8%           Duration of symptoms         2         1%           Age at biopsy         4         2%           Age at diagnosis         34         17%           Weight at diagnosis         1         <1%			
Age at presenting symptom       15       8%         Duration of symptoms       2       1%         Age at biopsy       4       2%         Age at diagnosis       34       17%         Weight at diagnosis       1       <1%			
Duration of symptoms         2         1%           Age at biopsy         4         2%           Age at diagnosis         34         17%           Weight at diagnosis         1         <1%			
Age at biopsy       4       2%         Age at diagnosis       34       17%         Weight at diagnosis       1       <1%			
Age at diagnosis       34       17%         Weight at diagnosis       1       <1%			
Weight at diagnosis         1         <1%			
Diagnosis during neonatal period         8         4%           Age at first contact with pediatric surgeon         1         <1%			
Age at first contact with pediatric surgeon       1       <1%			
Age at surgery       132       66%         Surgery during neonatal period       8       4%         Age at follow-up/study       71       36%         Age at redo surgery       4       2%         Weight at surgery       40       20%         Height at surgery       1       <1%			
Surgery during neonatal period       8       4%         Age at follow-up/study       71       36%         Age at redo surgery       4       2%         Weight at surgery       40       20%         Height at surgery       1       <1%	Age at first contact with pediatric surgeon		
Age at follow-up/study       71       36%         Age at redo surgery       4       2%         Weight at surgery       40       20%         Height at surgery       1       <1%			
Age at redo surgery       4       2%         Weight at surgery       40       20%         Height at surgery       1       <1%			
Weight at surgery         40         20%           Height at surgery         1         <1%			
Height at surgery		4	
Previous surgery       6       3%         Age at admission       2       1%         Marriage/Relationship status       4       2%         Place of residence       1       <1%	Weight at surgery	<u>40</u>	<u>20%</u>
Age at admission       2       1%         Marriage/Relationship status       4       2%         Place of residence       1       <1%		1	
Marriage/Relationship status       4       2%         Place of residence       1       <1%	Previous surgery	6	3%
Place of residence       1       <1%		2	1%
Salary / Income       2       1%         Mother language       1       <1%	Marriage/Relationship status	4	2%
Mother language       1       <1%	Place of residence	1	<1%
Socio-economic status         2         1%           Maternal education level         1         <1%	Salary / Income	2	1%
Maternal education level       1       <1%	Mother language	1	<1%
Education       5       3%         Special education services       1       <1%	Socio-economic status	2	1%
Special education services         1         <1%	Maternal education level	1	<1%
School for special education       1       <1%	Education	5	3%
Remedial teaching1<1%Occupation32%Length at time of surgery21%	Special education services	1	<1%
Occupation 3 2%  Length at time of surgery 2 1%		1	<1%
Length at time of surgery 2 1%	Remedial teaching	1	<1%
	Occupation	3	2%
BMI at time of surgery 1 <1%	Length at time of surgery	2	1%
	BMI at time of surgery	1	<1%

#### **Disease characteristics**

	n=	%
Initial clinical symptoms (cumulative)	<u>55</u>	28%
Abdominal distention (preoperative)	<u>19</u>	10%
Fever (preoperative)	3	1%
Delay passage of meconium	<u>25</u>	13%
Absent meconium release	2	1%
Time until first excretion of meconium	3	2%
Vomiting (preoperative)	<u>17</u>	9%
Lower intestinal obstruction (preoperative)	3	2%
Signs of intestinal obstruction (preoperative)	6	3%
Enterocolitis (preoperative)	<u>45</u>	23%
Causing pathogenic organisms enterocolitis	1	<1%
Constipation (preoperative)	19	10%
Diarrhea (preoperative)	2	1%
Intestinal perforation (preoperative)	10	5%
Neonatal jaundice (preoperative)	1	<1%
Poor feeding/ failure to thrive (preoperative)	14	7%
Anemia requiring blood transfusion	2	1%
Fatigue (preoperative)	2	1%
Melena (preoperative)	2	1%
HSCR diet and probiotics (preoperative)	2	1%
Other presenting symptoms	1	<1%
Not opening bowels (preoperative)	1	<1%
Distended bowel (preoperative)	1	<1%
Classic triad <sup>a</sup>	4	2%
Neonatal bowel obstruction (preoperative)	1	<1%
Need for glycerin enema's (preoperative)	2	1%
Toxic megacolon (preoperative)	1	<1%
Paleness (preoperative)	1	<1%
Urinary tract infection (preoperative)	1	<1%
Fecaloid mass (preoperative)	4	2%
Weakness (preoperative)	1	<1%
Explosive discharge of gas and stools after rectal examination	2	1%
Age at reflux enema method	1	<1%
History of central nervous system infection (preoperative)	1	<1%
Weight loss (preoperative)	1	<1%
Incidence of HSCR	7	3%
Prevalence of HSCR	2	1%
Serum total protein at time of surgery	1	<1%

Serum albumin at time of surgery	4	2%
Serum prealbumin at time of surgery	1	<1%
Hemoglobin at time of surgery	4	2%
White blood cells at time of surgery	1	<1%
Blood urea nitrogen at time of surgery	1	<1%
Extent of aganglionosis <sup>b</sup>	101	51%
Length of ileum involvement	1	<1%
Aganglionic segments extending to descending colon	3	2%
Aganglionic segments extending to transverse colon	2	1%
>30cm of aganglionotic length	1	<1%
Muscular sleeve >4cm	1	<1%
Dilated segments extending to ascending colon	1	<1%
Length of transition zone	3	2
Distance of transition zone to the terminal ileum	1	<1%
Distance of transition zone to the dentate line	1	<1%
Dependence of parenteral nutrition at surgery	2	1%
Intestinal dysplasia	1	1%

# Comorbidities

	n=	%
Associated anomalies	38	19%
Other major anomalies	2	1%
Incidence associated anomalies	1	<1%
Other diseases	3	2%
Major comorbidity	2	1%
Isolated associated anomaly	1	<1%
Co-existent developmental condition	1	<1%
Number of malformations	2	1%
Unspecified congenital malformations	2	1%
Congenital anomalies of eye, ears, face and neck	7	4%
Hemangioma of the scalp	1	<1%
Skin	2	1%
Trigonocephalia	1	<1%
Club feet	1	<1%
Cleft lip/palate	6	3%
Cardiovascular anomalies	40	20%

Congenital heart disease/anomaly	40	20%
Congenital circulatory system anomaly	1	<1%
Fallot's triad	2	1%
CHD with or without underlying syndrome	2	1%
Cardiac myopathy	1	<1%
Atrial septal defect	4	2%
Ventricular septal defect	6	3%
Bicuspid aortic valve	1	<1%
Aortic stenosis	1	<1%
Vena Galeni malformation	1	<1%
Hypoplastic left heart syndrome	2	1%
Congenital pulmonary anomaly	12	6%
Congenital central hypoventilation syndrome	4	2%
Congenital diaphragmatic hernia	2	1%
Bronchopulmonary dysplasia	1	<1%
Neurologic anomalies	<u>19</u>	10%
Congenital anomaly of nervous system	10	5%
Neurologic alterations	2	1%
Mental retardation	1	<1%
Hydrocephalus	1	<1%
Epilepsy	3	2%
Ganglioneuroblastoma	1	<1%
Ganglioneuroma	1	<1%
Congenital anomaly of digestive system	<u>19</u>	10%
Intestinal malrotation	3	2%
Anorectal malformation	4	2%
Gastroesophageal reflux	1	<1%
Duodenal atresia	3	2%
Small bowel atresia	2	1%
Esophageal atresia	1	<1%
Pyloric stenosis	1	<1%
Meckel's diverticulum	1	<1%
Congenital anomaly of musculoskeletal system	9	5%
Vertebral	2	1%
Osteogenesis imperfecta	1	<1%
Congenital anomalies of the urogenital system	23	12%
Renal/genitourinary anomalies	<u>23</u>	12%
Hypospadia	6	3%
UTI (really mentioned as associated anomaly)	3	2%
Neurogenic bladder requiring intermittent catheterization	1	<1%
Urological anomaly with or without underlying syndrome	1	<1%

Vesicoureteral reflux         3         2%           Arrophic kidney         1         <1%           Hydrocele         1         <1%           Single kidney         1         <1%           Kidney dysplasia         2         1%           Congenital hydronephrosis         1         <1%           Micropenis         1         <1%           Ureteral duplication         1         <1%           Kidney agenesis         1         <1%           Horseshoe kidney         1         <1%           Multicystic kidney disease         1         <1%           Unilateral kidney cyst         1         <1%           Bartter syndrome         1         <1%           Bartter syndrome         1         <1%           Britter syndrome         1         <1%           Cryogiobulinemic kidney failure         1         <1%           Thyroid disorders         6         3%           Diabetes         2         1%           Celiac disease         2         1%           Polydactyly         1         <1%           Visual impairment         2         1%           Hearing impairment         2         1%<	Genital anomaly	3	2%
Arrophic kidney         1         <1%			
Hydrocele		_	
Single kidney         1         <1%			
Kilney dysplasia         2         1%           Congenital hydronephrosis         2         1%           Micropenis         1         <1%			
Congenital hydronephrosis         2         1%           Micropenis         1         <1%			
Micropenis         1         <1%			
Ureteral duplication         1         <1%			
Kidney agenesis         1         <1%			-
Horseshoe kidney   1			
Multicystic kidney disease         1         <1%		1	<1%
Unilateral kidney cyst         1         <1%		1	
Posterior urethral valves         1         <1%		1	<1%
Hinman syndrome         1         <1%		1	<1%
Hinman syndrome         1         <1%	Bartter syndrome	1	<1%
Cryoglobulinemic kidney failure         1         <1%			
Thyroid disorders         6         3%           Diabetes         1         <1%		1	<1%
Diabetes         1         41%           Cellac disease         2         1%           Polydactyly         1         <1%		6	3%
Polydactyly         1         <1%		1	<1%
Visual impairment         3         2%           Hearing impairment         2         1%           Hematologic problem         2         1%           Endocrinologic problem         2         1%           Umbilical hernia         1         <1%	Celiac disease	2	1%
Visual impairment         3         2%           Hearing impairment         2         1%           Hematologic problem         2         1%           Endocrinologic problem         2         1%           Umbilical hernia         1         <1%	Polydactyly	1	<1%
Hematologic problem       2       1%         Endocrinologic problem       2       1%         Umbilical hernia       1       <19%		3	2%
Endocrinologic problem         2         1%           Umbilical hernia         1         <1%	Hearing impairment	2	1%
Umbilical hernia         1         <1%	Hematologic problem	2	1%
Primary immunodeficiency disease         1         <1%           Adenoid hypertrophy         1         <1%	Endocrinologic problem	2	1%
Adenoid hypertrophy       1       <1%	Umbilical hernia	1	<1%
Hip dysplasia       1       <1%	Primary immunodeficiency disease	1	<1%
Syndromal, genetic and chromosomal disorders         80         40%           Trisomy 21 (Down)         65         33%           Bardet-Biedl Syndrome         5         3%           Mowat-Wilson         9         5%           Hair-cartilage hypoplasia         4         2%           DiGeorge syndrome         1         <1%	Adenoid hypertrophy	1	<1%
Trisomy 21 (Down)         65         33%           Bardet-Biedl Syndrome         5         3%           Mowat-Wilson         9         5%           Hair-cartilage hypoplasia         4         2%           DiGeorge syndrome         1         <1%	Hip dysplasia	1	<1%
Bardet-Biedl Syndrome       5       3%         Mowat-Wilson       9       5%         Hair-cartilage hypoplasia       4       2%         DiGeorge syndrome       1       <1%	Syndromal, genetic and chromosomal disorders	80	40%
Mowat-Wilson       9       5%         Hair-cartilage hypoplasia       4       2%         DiGeorge syndrome       1       <1%	Trisomy 21 (Down)	<u>65</u>	33%
Hair-cartilage hypoplasia       4       2%         DiGeorge syndrome       1       <1%	Bardet-Biedl Syndrome	5	3%
DiGeorge syndrome       1       <1%	Mowat-Wilson	9	5%
Ondine       4       2%         Pallister Hall       1       <1%	Hair-cartilage hypoplasia	4	2%
Pallister Hall       1       <1%	DiGeorge syndrome	1	<1%
Gilbert's syndrome       1       <1%	Ondine	4	2%
Currarino syndrome       2       1%         Noonan syndrome       1       <1%	Pallister Hall	1	<1%
Noonan syndrome         1         <1%	Gilbert's syndrome	1	<1%
IgA deficit and celiac disease1<1%G6PD Deficiency1<1%	Currarino syndrome	2	1%
G6PD Deficiency         1         <1%	Noonan syndrome	1	<1%
EDNRB mutation 1 <1%	IgA deficit and celiac disease	1	<1%
	G6PD Deficiency	1	<1%
RET mutation 4 2%	EDNRB mutation	1	<1%
'   = 7	RET mutation	4	2%
Syndromal (unspecified) 3 2%	Syndromal (unspecified)	3	2%

Chromosomal anomaly	5	3%
Genetic anomalies	2	1%
Haddad	7	4%
Shah-Waardenburg	8	4%
Bresheck syndrome	3	2%
Marker-chromosome syndrome	2	1%
Marcus Gunn syndrome	2	1%
Kabuki syndrome	2	1%
Asperger syndrome	1	<1%
MEN 2A syndrome	2	1%
Klinefelter	1	<1%
Translocation 20-21	1	<1%
13q deletion syndrome	2	1%
Deletion chromosome 1	1	<1%
phox2b mutation	1	<1%
Goldberg-Sphrintzen syndrome	1	<1%
McKusick-Kaufman syndrome	1	<1%
1q partial trisomy, 3p partial monosomy	1	<1%
Trisomy 20q	1	<1%
Coffin-Lowry syndrome	1	<1%
Smith-Lemli-Opitz syndrome	1	<1%
Beckwith-Wiedeman syndrome	1	<1%
Chromosome 22 abnormalities	2	1%
Turner	1	<1%
Cat-eye syndrome	1	<1%

#### **Parental characteristics**

		n=	%
Age mother		5	3%
Age father		1	<1%
Occupation parents		1	<1%
Single parity (first and only child)		1	<1%
Insurance		9	5%

#### **SUPPLEMENTARY 4: Extracted treatment and care process characteristics**

\*As several parameters could arguably be included into more than one category, categorization was determined through agreement between the first two authors. Furthermore, we arranged the parameters by topic, such as diagnostics, perioperative workup, primary treatment, treatment of complications, to facilitate the comparison of variation in studied parameters among similar subjects. Underlined items were studied in more than 5% of included publications. The items indicated as 5% but not underlined were identified in 4.5% of the included publications.

### **Hospital structure**

	n=	%
Medical costs	8	4%
Hospital volume (number of patients)	3	2%
Specific surgeon performing surgery	3	2%
Received sufficient information about HSCR	1	<1%
Follow-up rate	<u>21</u>	11%
Total number of follow-ups	1	<1%
Number of counseling sessions during first 6 months	1	<1%
Number of planned visits	4	2%
Time since surgery until follow-up	6	3%
Misdiagnosis rate	5	3%

# Diagnostics

	n=	%
Prenatal ultrasound	1	<1%
Prenatal ultrasound: bowel dilation	1	<1%
Prenatal ultrasound: polyhydramnios	1	<1%
Prenatal ultrasound: oligohydramnios	1	<1%
Anorectal manometry (preoperative)	13	7%
Age at anorectal manometry	1	<1%
Findings preoperative anorectal manometry: lack of the rectoanal inhibitory reflex	1	<1%
Findings preoperative anorectal manometry: rectal rest pressure	3	2%
Findings preoperative anorectal manometry: anal canal rest pressure	1	<1%
Findings preoperative anorectal manometry: anal canal length (in cm)	1	<1%
Findings preoperative anorectal manometry: amplitude anal contraction (in mmHg)	1	<1%
Findings preoperative anorectal manometry: frequency anal contraction (per minute)	1	<1%
Preoperative contrast enema	<u>27</u>	14%
Preoperative contrast enema: wrong or correct determination of transitional zone	6	3%
Contrast enema examinations with delayed X-ray	1	<1%
Contrast study: location of barium residue	1	<1%
Contrast study: clear transition zone	3	2%
Contrast study: barium retention for >24h	1	<1%
Contrast study: microcolon	1	<1%
Contrast study: relationship caliber change and proximal ends of barium residue	1	<1%

Rectal biopsies	<u>26</u>	13%
Age at rectal suction biopsies	2	1%
Number of rectal suction biopsies	3	2%
Rectal mucosal biopsy	5	3%
Rectal full-thickness biopsy	6	3%
Distance from biopsy taken and dentate line	1	<1%
Histochemical studies for acetylcholinesterase	4	2%
Histochemical studies for hematoxylin and eosin	2	1%
Histochemical studies for calretinin	2	1%
Abdominal X-ray (preoperative)	9	5%
Findings preoperative abdominal X-ray: swelling of intestinal loops	1	<1%
Findings preoperative abdominal X-ray: lack of distal air	2	1%
Findings preoperative abdominal X-ray: fecaloma/faecal stasis	2	1%
Findings preoperative abdominal X-ray: air fluid levels	6	3%
Findings preoperative abdominal X-ray: cut-off sign	5	3%
Findings preoperative abdominal X-ray: distended bowel loops	5	3%
Findings preoperative abdominal X-ray: Sawtooth appearance with irregular mucosal lining	4	2%
Findings preoperative abdominal X-ray: Pneumatosis intestinalis	4	2%
Findings preoperative abdominal X-ray: features of intestinal obstruction	1	<1%
Leukocytosis	6	3%
Left shift on blood count	4	2%
Radiological and intraoperative transition zone match	2	1%
Intraoperative biopsies	<u>18</u>	9%
Intraoperative gross transition zone	2	1%
Intraoperative frozen section with ganglion cells	6	3%
Histopathological analysis of the appendix	1	<1%
Sensitivity and specificity of appendix as diagnostic tool	1	<1%
Histopathological analysis: development (maturity) of ganglion cells in proximal intestine	2	1%
Genetic testing	1	<1%
Full thickness colon biopsies during enterostomy	1	<1%

### Perioperative work-up

-			
	Colon irrigations (mechanical bowel preparation) (preoperative)	<u>18</u>	<u>9%</u>
		1	

Effective preoperative bowel preparation by rectal washout	2	1%
Preoperative management with repeated bowel washes	1	<1%
Duration of bowel preparation	3	2%
Rectal wash-outs	4	2%
Rectal wash-outs at home	3	2%
Duration of indwelling anal catheter for coloclysis	1	<1%
Time used for each coloclysis	1	<1%
Amount of liquid used for each coloclysis	1	<1%
Intestinal tract cleanliness after coloclysis	1	<1%
Degree of comfort of coloclysis	1	<1%
Perianal skin redness after coloclysis	1	<1%
Complications after coloclysis	1	<1%
Discharge time after coloclysis	1	<1%
Enterocolitis during coloclysis	1	<1%
Subjective feeling of infant after coloclysis	1	<1%
Duration of restoration of child's faeces color and smell to normal (in days)	1	<1%
Duration of relief of abdominal distension and vomiting disappearance (in days)	1	<1%
Duration of restoration of appetite to normal (in days)	1	<1%
Intravenous antibiotics 1-2 days preoperative to 3 days postoperative	5	3%
Duration intravenous antibiotics	4	2%
Duration intravenous fluid suppletion/administration	1	<1%
Feeding gastrostomy/jejunostomy	3	2%
Preoperative stoma / Primary stoma	<u>71</u>	36%
Preoperative ileostomy	<u>16</u>	8%
Preoperative jejunostomy	2	1%
Preoperative colostomy	20	10%
Preoperative transverse colostomy	2	1%
Preoperative sigmoidostomy	2	1%
Blowhole transverse colostomy	1	<1%
Stoma without initial trial rectal washouts	1	<1%
Colectomy before reconstruction	1	<1%
Age at preoperative stoma	9	5%
Rate histopathologically proven/diagnosis before surgery	3	2%
Home before definitive surgery	1	<1%
Preoperative complications	1	<1%
Irrigations performed during admission	2	1%
Time (in days) from histopathological diagnosis to surgery	8	4%
Time (in days) from histopathological diagnosis to reconstruction	1	<1%
Time (in days) from symptoms onset to contact with pediatric surgeon	1	<1%

Time (in days) from symptoms onset to surgery	1	<1%
Time from first contact with pediatric surgeon to surgery	5	3%

## Primary treatment

	n=	%
Type of repair	113	<u>57%</u>
Single- or multiple staged	<u>19</u>	20%
Causes of staged repair	2	1%
Intraoperative complications	<u>18</u>	9%
Rate primary surgery without enterostomy	2	1%
Number of stoma's	1	<1%
Time (in months) from surgery until closure of stoma	4	2%
Age at closure of ileostomy	1	<1%
Time between stoma and radical surgery	4	2%
Stoma closure at time of definitive repair	5	3%
Stoma at time of surgery	3	2%
Duration oral antibiotics	1	<1%
Coloanal anastomosis: interrupted sutures	1	<1%
Coloanal anastomosis	1	<1%
Anastomotic incongruence	1	<1%
Plication procedure	1	<1%
Number of stitches	1	<1%
Ileoanal anastomosis	2	1%
Peroperative ileostomy	1	<1%
Operation duration	<u>46</u>	23%
Laparoscopic phase duration	1	<1%
Conversion laparoscopy to laparotomy	<u>14</u>	<u>7%</u>
Laparoscopy or laparotomy or trans-anal	<u>40</u>	<u>20%</u>
Abdominal approach using laparotomy	3	2%
Insertion of additional trocar during laparoscopy	2	1%
Number of ports used during laparoscopic surgery	2	1%
Peroperative impression of colon	1	<1%
Anal dissection time	1	<1%
Length of resected aganglionic and dilated segments	<u>40</u>	20%
Length of remaining intestines	3	2%
Length of remaining small intestine	1	<1%
Level of pull-through	1	<1%
Level of anastomosis	1	<1%

Antegrade Colonic Enema (ACE)	<u>14</u>	<u>7%</u>
Indications for ACE	2	1%
Time (in days) to start feeding	<u>11</u>	<u>6%</u>
Time (in days) to full enteral feeding	5	3%
Need for parenteral nutrition postoperatively	8	4%
Duration parenteral nutrition	4	2%
Need for a gastrostomy	4	2%
Anal tube	1	<1%

## **Treatment of complications**

	n=	%
Anal dilatations	<u>33</u>	17%
Anal dilatation under general anesthesia	<u>12</u>	6%
Anal dilatation, 2 weeks postoperatively	2	1%
Anal dilatation, 2 weeks postoperatively up to 6 months	1	<1%
Anal dilatations, 1 year postoperatively	1	<1%
Anal calibrations, 1 year postoperatively	1	<1%
Median number of anal dilatations	3	2%
Gentle calibrating and dilating weekly	1	<1%
Dilatation for stricture	8	4%
Number of calibrations	2	1%
Examination under anesthesia	3	2%
Postoperative dilatations duration (in days)	1	<1%
HAEC pathological grade system: stenosed segment (Elhalaby et al.)	2	1%
HAEC pathological grade system: transitional segment (Elhalaby et al.)	1	<1%
HAEC pathological grade system: dilated segment (Elhalaby et al.)	1	<1%
HAEC pathological grade system: overall resected (Elhalaby et al.)	1	<1%

## Treatment of long-term morbidity

	n=	%
Current contact with medical care (at time of study)	3	2%
<u>Duration follow-up</u>	<u>78</u>	39%
HSCR consultations 1 year postoperatively	1	<1%
Time between leaving the hospital and the first counseling postoperatively (in days)	2	1%

Toilet training	1	<1%	

## Follow-up

	n=	%
Anorectal manometry: follow-up	12	6%
Complete manometry	1	<1%
Age at manometry	1	<1%
Anorectal manometry (follow-up): enhanced pressure curve	1	<1%
Anorectal manometry (follow-up): pressure response to maintained voluntary contraction	1	<1%
Anorectal manometry (follow-up): pressure response to perianal stimulation	1	<1%
Anorectal manometry (follow-up): pressure response to voluntary contracting	1	<1%
Anorectal manometry (follow-up): ano-anal reflex	1	<1%
Anorectal manometry (follow-up): cough reflex	2	1%
Anorectal manometry (follow-up): rectosphincteric reflex	1	<1%
Anorectal manometry (follow-up): resting pressure	7	4%
Anorectal manometry (follow-up): squeeze pressure	4	2%
Anorectal manometry (follow-up): simple pressure curve	1	<1%
Anorectal manometry (follow-up): RAIR (relaxation pressure during rectal balloon distention)	3	2%
Anorectal manometry (follow-up): mean sphincter pressure	2	1%
Anorectal manometry (follow-up): sphincter pressure response to coughing	1	<1%
Anorectal manometry (follow-up): length of high pressure zone	1	<1%
Anorectal manometry (follow-up): length verge to centre	1	<1%
Anorectal manometry (follow-up): rectal compliance	1	<1%
Anorectal manometry (follow-up): anal canal resting pressure	2	1%
Anorectal manometry (follow-up): inhibitory reflex	1	<1%
Anorectal manometry (follow-up): Anal canal length (cm)	1	<1%
Anorectal manometry (follow-up): Amplitude anal contraction	1	<1%
Anorectal manometry (follow-up): frequency anal contraction	1	<1%
Anorectal manometry (follow-up): endurance squeeze	1	<1%
Anorectal manometry (follow-up): defecation patterns	1	<1%
Profilometry: rectal volume	1	<1%
Anoendoscopy: follow up	1	<1%
Anoendoscopy (follow-up): recognition of the IAS	1	<1%
Anoendoscopy (follow-up): IAS defects yes or no	1	<1%

Anoendoscopy (follow-up): number of IAS defects in individual patients	1	<1%
Anoendoscopy (follow-up): total angular distribution of IAS defects	1	<1%
Anoendoscopy (follow-up): EAS defects yes or no	1	<1%
Anoendoscopy (follow-up): size of IAS defects	1	<1%
Anoendoscopy (follow-up): IAS thickness	1	<1%

#### **SUPPLEMENTARY 5: Extracted outcomes**

\*As several parameters could arguably be included into more than one category, categorization was determined through agreement between the first two authors. Furthermore, we arranged the parameters by topic, such as complications, readmission and reoperation, morbidity, to facilitate the comparison of variation in studied parameters among similar subjects. Underlined items were studied in more than 5% of included publications. The items indicated as 5% but not underlined were identified in 4.5% of the included publications.

#### **Complications**

	n=	%
Blood loss	<u>41</u>	21%
Intraoperative blood transfusion	6	3%
Postoperative blood transfusion	6	3%
Chronic low gastrointestinal bleeding needing blood transfusion	1	<1%
Bleeding anemia requiring transfusion	2	1%
Bleeding from anastomosis	1	<1%
Intraoperative blood loss	4	2%
Intraoperative blood loss during laparoscopic phase	1	<1%
Time until onset of gastrointestinal bleeding	1	<1%
Wound issues	<u>32</u>	16%
Wound dehiscence	<u>11</u>	<u>6%</u>
Wound infection	<u>27</u>	14%
Time (in weeks) until healing wounds	1	<1%
Incisional hernia	3	2%
Perianal issues	38	19%
Perianal dermatitis	9	5%
Diaper rash	1	<1%
Anal pain score	1	<1%
Perianal erosion	5	3%
Anal excoriations	<u>24</u>	12%
Injection site complications after botox	2	1%
Perianal fistula	2	1%

Organ/space surgical site infection (abdominal infection)	4	2%
Alternative	10	50/
Abcess	10	5%
Cuff abcess	3	2%
Perineal abcess	2	1%
Itches	1	<1%
Persistent internal sphincter achalasia	4	2%
Pelvic infection	3	2%
Infection	<u>10</u>	<u>5%</u>
Residual aganglionosis	<u>24</u>	<u>12%</u>
Incomplete/Transitional zone pull-through	<u>10</u>	<u>5%</u>
Retained aganglionotic segment	1	<1%
Residual aganglionosis because of error in histologic interpretation	2	1%
Residual aganglionosis because of sampling error	1	<1%
Residual aganglionosis because of error in surgical technique	1	<1%
Ganglion cell loss	1	<1%
Hypoganglionosis	2	1%
Immature ganglion cells	2	1%
Intestinal neuronal dysplasia type B	1	<1%
Repeat biopsy normal	1	<1%
Repeat biopsy postoperative	2	1%
Anastomotic leakage	<u>56</u>	28%
Anastomotic dehiscence/retraction	8	4%
Anastomotic abces	1	<1%
Anastomotic stricture/stenosis	<u>76</u>	38%
Recurrent stricture	2	1%
Anastomotic volvulus	1	<1%
Outlet obstruction	4	2%
Stenosis of muscular cuff	5	3%
Obstructed pouch	1	<1%
Anastomotic fistula	7	4%
Rectovestibular fistula/urinary	5	3%
Fistula to the seminal vesicle	2	1%
Rectovaginal fistula	2	1%
Enterocutaneous fistula	2	1%
Urinary-rectal fistula	3	2%
Intestinal obstruction	49	25%
Anorectal obstruction	1	<1%
Sub-obstruction due to adhesions	1	<1%
Ileus/bowel obstruction due to adhesions	20	10%
Paralytic obstruction	1	<1%
Intussusception	2	1%
Hospitalization for obstruction	1	<1%
Twisted bowel	7	4%

Peritonitis	2	1%
Pelvic floor fibrosis	1	<1%
Osteomyelitis	1	<1%
Pouchitis	3	2%
Short bowel syndrome	3	2%
Sepsis	<u>13</u>	<u>7%</u>
Bloodstream infection	2	1%
Rectal prolapse	<u>15</u>	<u>8%</u>
Total colon prolapse	3	2%
Pneumonia	3	2%
Perforation colon	1	<1%
Intestinal perforation	8	4%
latrogenic dehiscence when inserting rectal catheter	1	<1%
latrogenic/incidental injury	2	1%
Bowel injury	3	2%
Urethral injury	5	3%
Ureter injury	2	1%
Vaginal injury	3	2%
Retraction	2	1%
Recurrence	1	<1%
Toxic hepatitis	1	<1%
Hepatic failure	1	<1%
Botulinum toxin	<u>31</u>	16%
Botulinum toxin injection for outlet obstruction	9	5%
Number of botulinum toxin injection treatments	6	3%
Multiple botulinum toxin injection	1	<1%
Delay between first and second injection	1	<1%
Age at first botulinum toxin injection treatment	4	2%
Weight at first botulinum toxin injection treatment	1	<1%
Time (in days) pull-through to botulinum injection	1	<1%
Time from botulinum injection to follow-up	1	<1%
Effect of (first) botulinum injection	4	2%
Myectomy because of bowel outlet obstruction	4	2%
Postoperative Hirschsprung's Associated Enterocolitis (HAEC)	<u>127</u>	64%
Hospitalized for enterocolitis at least once	8	4%
At least one episode of enterocolitis	8	4%
Single episode of enterocolitis	5	3%
Multiple episodes of enterocolitis	<u>14</u>	<u>7%</u>
More than 3 episodes of HAEC	1	<1%
Rate of HAEC in first postoperative year	1	<1%
Incidence of HAEC	<u>13</u>	<u>7%</u>

Disabase Associated Estates 182 B		70/
Hirschsprung Associated Enterocolitis Recurrence	<u>14</u>	<u>7%</u>
HAEC treated by conservative management (non-operative)	<u>16</u>	8%
Number of episodes of enterocolitis	7	4%
Age at time of HAEC	1	<1%
Time between surgery and ulceration diagnosis (in days)	1	<1%
Time between enterocolitis and surgery (in days)	5	3%
Time from pull-through to initial episode of HAEC	3	2%
Time from pull-through to second episode of HAEC	1	<1%
Endoscopy performed in HAEC	1	<1%
HAEC endoscopy: Longitudinal peri anastomosis Crohn like ulcerations	1	<1%
Type of medication for ulceration HAEC	1	<1%
Type of medication for enterocolitis	1	<1%
Broad-spectrum antibiotic therapy for enterocolitis	2	1%
Duration of antibiotics	1	<1%
Microorganisms in stool during enterocolitis	1	<1%
Severity of HAEC (according to grading system by Elhalaby et al)	3	2%
Severity of HAEC (according to 'standardized' grading system)	1	<1%
Severity of HAEC (clinical, according to Murphy et al.)	1	<1%
HAEC score (by Pastor et al.)	5	3%
HAEC score at diagnosis	2	1%
Consistent HAEC score (Pastor et al.) in every episode	1	<1%
Intestinal failure	4	2%
Intestinal failure: need for ltx/transplantation	3	2%
End-stage liver disease	2	1%
Intestinal failure-associated liver disease	1	<1%
Misplacement of an epidural catheter	1	<1%
Respiratory complication	6	3%
Hemothorax	1	<1%
Upper respiratory tract infection	2	1%
Neurologic complication	3	2%
Seizures	2	1%
Stoma complications	<u>15</u>	8%
Stoma stenosis	3	2%
Stoma prolapse	7	4%
High-output stoma	3	2%
Stoma needing revision	1	<1%
Ostomy prolapse requiring surgical revision	2	1%
Number of surgeries on stoma	1	<1%
Stoma leakage	1	<1%

Stoma excoriation	1	<1%
Redness of skin around stoma	2	1%
Stoma retraction	2	1%
Parastomal hernia	1	<1%
Contrast enema in follow-up	1	<1%
Reintubation	1	<1%
Early postoperative complications	26	13%
Postoperative complications within 1 month after pull-through	3	2%
Adverse reaction rate	1	<1%
Late/long term complications	6	3%
Complications	30	<u>15%</u>
Postoperative complications unrelated to surgery	1	<1%
Number of times hospitalized for complications of disease	3	2%
Complication rate	2	1%
Presentation from home	1	<1%
Number of emergency visits	5	3%
Acute HSCR consultations 1 year postoperatively	1	<1%
Postoperative pain	3	2%
Epidural catheter complication	1	<1%
Received opiates not in compliance with normal postoperative course	1	<1%
Postoperative nasogastric decompression for 12-24 hours	1	<1%
Stoma at time of follow-up	21	11%

## Readmission and reoperation

	n=	%
Readmission	<u>25</u>	13%
Reoperation	<u>85</u>	43%
Reoperation type	<u>10</u>	<u>5%</u>
Time between first surgery and reoperation	3	2%
Reoperation due to complications (no timeframe)	<u>10</u>	<u>5%</u>
Reoperation due to anastomotic leakage	8	4%
Reoperation due to twisted bowel / volvulus	7	4%
Reoperation due to perforation after biopsy	1	<1%
Reoperation due to perforation after postoperative calibration	1	<1%
Reoperation due to postoperative fistualization between bowel and urinary tract	4	2%
Reoperation due to wound dehiscence	1	<1%
Reoperation due to bleeding	2	1%
Reoperation due to stricture	9	5%

Reversal ileostomy that was closed earlier	2	1%
Reoperation due to transition-zone pull-through	7	4%
Reoperation due to residual aganglionosis	10	5%
Reoperation due to wall abcess	3	2%
Secondary colostomy due to fistula	2	1%
Reoperation: ileostomy	5	3%
Reoperation for bowel resection	2	1%
Number of reoperations	5	3%
Reoperation due to residual rectal spur (post Duhamel)	5	3%
Reoperation: intestinal transplantation	2	1%
Reoperation: false negative biopsy	1	<1%
Reoperation due to adhesive intestinal obstruction	5	3%
Reoperation due to post myectomy persistence of symptoms	1	<1%
Reoperation due to fecal fistula	1	<1%
Reoperation due to anal sphincter tear secondary to dilated colon in long segment disease	1	<1%
Number of unplanned/emergency surgeries	5	3%
At least one unplanned/emergency surgery	1	<1%
Reoperation within 30 days	1	<1%
Reoperation within 1 year	1	<1%
Abnormal histological findings on full-thickness biopsies during reoperation	1	<1%
Number of surgeries	3	2%
Number of laparotomies	1	<1%
Number of episodes of general anaesthesia (before 2 years of age)	1	<1%
Need for transfer to a pediatric surgical center	1	<1%

<u>10</u>

2

<u>5%</u>

1%

2%

#### Growth

Number of hospitalizations

Reoperation due to obstruction/occlusion

Laparotomy with adhesiolysis and ileostomy because of adhesions

	n=	%
Growth/Weight/Failure to thrive	<u>32</u>	<u>16%</u>
BMI at time of follow-up	7	4%
Height (in cm) at time of follow-up	8	4%
Weight (in kg) at time of follow-up	<u>13</u>	<u>7%</u>
Failure to thrive according to growth charts that correlate height, weight and age	3	2%
Growth	3	2%
Weight-for-age	4	2%

Height-for-age	1	<1%
Nutritional status during follow-up	7	4%
Stunting	2	1%
Underweight	1	<1%
Head circumference at time of follow-up	1	<1%

# Morbidity

	n=	%
Gastrointestinal symptoms during follow-up	40	20%
Pain during defecation	3	2%
Fecal impaction	6	3%
Fecal loading	1	<1%
Abdominal pain	7	4%
Intensified flatulence / bad smelling gas	3	2%
Halitosis	1	<1%
Intestinal rumbling	1	<1%
Diarrhea	12	6%
Diarrhea with explosive stool	4	2%
Diarrhea with foul smelling stool	5	3%
Diarrhea with bloody stool	5	3%
Stool retention with explosive stools at night	1	<1%
Enterospasm	1	<1%
Heartburn	1	<1%
Eructation	1	<1%
Simple gastroenteristis requiring hospitalization	2	1%
Fever	10	<u>5%</u>
Abdominal distension	<u>18</u>	9%
Vomiting	4	2%
Lethargy	3	2%
Explosive discharge of gas and stool on rectal exam	3	2%
Decreased peripheral perfusion	4	2%
Previous history of suspected enterocolitis	5	3%
Enterocolitis before aganglionosis diagnosis	1	<1%
Enterocolitis between aganglionosis diagnosis and corrective surgery	1	<1%
Inflammatory bowel disease (IBD)	1	<1%
Age at IBD diagnosis	1	<1%
Prevalence of IBD	1	<1%
IBD for which surgery/medication	1	<1%
Crohn's disease	2	1%
Ulcerative colitis	2	1%
Ulcerative ileitis	1	<1%

Intestinal continuity	2	1%
Constipation	96	48%
Constinution: bloating	3	2%
Constipation: flatulence	2	1%
Constipation: need for repeated defecations to empty the rectum	1	<1%
Consupation. Need for repeated defectations to empty the rectum	1	170
Constipation: need to strain at defecation / difficult defecation	4	2%
Constipation: supporting around anus at defecation	1	<1%
Constipation: manageable with diet	<u>12</u>	<u>6%</u>
Constipation: manageable with laxatives	<u>15</u>	8%
Constipation: manageable with enema	<u>14</u>	<u>7%</u>
Recurrent constipation	<u>12</u>	<u>6%</u>
Duration of constipation symptoms after surgery	1	<1%
Fecaloma formation	1	<1%
Cleveland Clinic Constipation Scoring System	3	2%
Hospitalization for constipation	2	1%
Lumpy or hard stools	1	<1%
Incomplete evacuation	1	<1%
Manual maneuvers	1	<1%
Form of stool/consistency	<u>15</u>	8%
Defecation frequency	<u>52</u>	26%
Defecation frequency, 1 month postoperatively	4	2%
Defecation frequency, 1 week postoperatively	2	1%
Defecation frequency, 3 months postoperatively	4	2%
Defecation frequency, last day of hospital stay	2	1%
Time (in months) until normal defecation frequency	3	2%
Defecation frequency, early postoperative	1	<1%
Defecation frequency after two years	3	2%
Defecation frequency after six months	5	3%
Defecation frequency before six months	1	<1%
Defecation frequency after one year	1	<1%
Defecation frequency after one month	1	<1%
Defecation frequency after nine months	1	<1%
Normal defecation function	<u>37</u>	19%
Normal anal defecation function	6	3%
		-10/
Regular defecation at night time	1	<1%
Normal sense of defecation control	1	2%
Normal sense of defecation control  Feeling need for defecation	3	2%
Normal sense of defecation control	3 <u>13</u>	2% <u>7%</u>
Normal sense of defecation control  Feeling need for defecation  Voluntary bowel movement	3 13 6	2% 7% 3%

Ability to hold back defecation	13	7%
Rectal sensation	5	3%
Sense of stool condition	1	<1%
Time required for bowel movement	2	1%
Bowel function deteriorating during viral infections	1	<1%
Sensation for flatulence	2	1%
Control of bowel movement	2	1%
Number of bowel movements per week	1	<1%
Number of bowel movements per day	2	1%
Regular bowel movement	1	<1%
Defecation urgency	6	3%
Urgency: deferring time loose stool (in minutes)	1	<1%
Urgency: deferring time solid stool (in minutes)	1	<1%
orgency, deterning time solid stool (in minutes)	1	<1%
Urgency: need to rush to the toilet	1	<1%
Urgency: use of pad daytime	4	2%
Urgency period	2	1%
<u>Incontinence</u>	<u>107</u>	<u>54%</u>
Soiling	<u>72</u>	36%
Urge incontinence	2	1%
Fecal contamination/fecal accidents	<u>17</u>	9%
Incontinence: Miller incontinence score	2	1%
Incontinence: Postoperative Fecal Incontinence Score	1	<1%
Incontinence: Jorge-Wexner score	1	<1%
Baylor Continence Scale	2	1%
Wingspread criteria	4	2%
Visick score	1	<1%
Continence evaluation score	1	<1%
Incontinence in children >5 years	1	<1%
Occasional incontinence	1	<1%
Overflow incontinence	1	<1%
Incidents of fecal incontinence at least once a week	1	<1%
Daily incontinence	1	<1%
Required (night) diapers	4	2%
Number of fecal accidents	3	2%
Social continence	1	<1%
Involuntary loss of stools	1	<1%
Involuntary loss of stools (only at night)	2	1%
Involuntary loss of stools when provoked (physical activities, emotions, coughing, sneezing)	1	<1%
Impaired continence	1	<1%
Duration of fecal incontinence	1	<1%
Datation of room monumento	-	~± /U

Nocturnal enuresis	1	<1%
Child pees in underwear during the day	1	<1%
Volume of pee in underwear	1	<1%
Rate that child pees in the bathroom	1	<1%
Rate that child rushes to the bathroom	1	<1%
Rate that child holds pee by crossing legs/sitting down	1	<1%
Rate that pee hurts	1	<1%
Rate that child wets the bed	1	<1%
Rate that child wakes up to pee at night	1	<1%
Rate that peeing starts and stops	1	<1%
Rate that child has to push or wait for the pee	1	<1%
Dysfunctional elimination	1	<1%
Shape of flowmetry curve	1	<1%
Voided volume	1	<1%
Time of flow	1	<1%
Max. flow rate	1	<1%
Time to max. flow	1	<1%
Flow rate	1	<1%
Post-void residual	1	<1%
Discontinuous flow	1	<1%
Residual urine volume	1	<1%
Renal tract ultrasound	1	<1%
Level of urinary care necessary	1	<1%
Time until disappearance dilated colonic segments	1	<1%
Bowel function problems that affected choice of occupation	1	<1%
Bowel care preventing the child to leave the house	2	1%
Bowel care making child afraid to go outside	1	<1%
Afraid to go out due to fecal incontinence	1	<1%
School absenteeism	2	1%
Patients worrying about smell of their fecal incontinence	1	<1%
Bowel function had negative impact on daily life	1	<1%
Bowel care preventing the parent to leave the house	1	<1%
Bowel problems affecting relations parents	2	1%
Bowel problems causing anxiety in parents	2	1%
Parents worrying about smell of their child's fecal incontinence	1	<1%
Bowel problems affecting employment/job of parents	1	<1%
Bowel problems affecting household tasks of parents	2	1%
Regular visits psychologist as parent	1	<1%
Current contact with psychologist as parent	1	<1%

Sexual functional outcomes	1	<1%
Normal erectile functioning (Erectile Hardness Score)	1	<1%
Normal electric functioning (Electric Hardiess Score)	1	170
Age at first ejaculation	1	<1%
Age of coital debut	1	<1%
Age at menarche	1	<1%
Conception desire	1	<1%
Fertility issues or treatment	2	1%
Having children	2	1%
Presenting symptoms hydrosalpinx	1	<1%
Unilateral hydrosalpinx	1	<1%
Bilateral hydrosalpinx	1	<1%
Sexually active at time of diagnosis hydrosalpinx	1	<1%
Unilateral salpingectomy	1	<1%
Bilateral salpingectomy	1	<1%
Ultrasound guided drainage of hydrosalpinx	1	<1%
Length of primary hospital stay	<u>71</u>	36%
Length of cumulative hospital stay	4	2%
Length of primary hospital stay after one-stage repair	3	2%
Length of primary hospital stay after two-stage repair	2	1%
Time from discharge until first counseling	1	<1%
Number of inpatient days in first year of life	1	<1%
Parent-reported learning problems	1	<1%

# Quality of life

	n=	%
Quality of Life	<u>28</u>	14%
HSCR and ARM QoL scale (HAQL)	4	2%
SF-36	5	3%
GIQLI	4	2%
Peds QL	8	4%
Peds QL (Psychosocial score)	3	2%
Peds QL (Physical score)	3	2%
Peds QoL Generic Core scale	1	<1%
Peds QoL General wellbeing score	1	<1%
Peds QoL Family Impact Module	2	1%
PedsQLTM4.0	2	1%

Number of PedsQL surveys completed	1	<1%
Fecal Incontinence and Constipation Quality of Life	2	1%
WHO QOL-BREF	1	<1%
AQLCAFI - Assessment of QoL in Children and Adolexcents with fecal incontinence	1	<1%
Relationship of caregiver respondent	1	<1%
CHQ-PF50	1	<1%
CHQ-CF87	2	1%
WHOQOL-100	2	1%
Scoring system by Bai et al. In patients with HD	1	<1%
Barrena score	1	<1%
TCCQOL - total score	1	<1%
TCCQOL - physical function	1	<1%
TCCQOL - motor function	1	<1%
TCCQOL - self-care ability	1	<1%
TCCQOL - cognitive ability	1	<1%
TCCQOL - communicative ability	1	<1%
TCCQOL - positive emotion	1	<1%
TCCQOL - negative emotion	1	<1%
HAQL - Sexual functionign	1	<1%
KIDSCREEN 52	1	<1%
Need for adressing sexuality with special interest to the congenital anomaly during medical care	1	<1%
Parent satisfaction	4	2%
Compliance of parents	1	<1%
Rate of satisfaction for discharge without treatment	1	<1%
PSE-HDAM (Patient self-efficacy in the management of home care of children with HD and ARM)	1	<1%

# Mortality

			n=	%
Mortality			<u>51</u>	26%
Survival			7	4%
Cause of death			<u>17</u>	9%
Age at death			3	2%
Mortality rate preopera	ative enterocolitis		2	1%

## Other

		0/
Coomatia vagult	n=	%
Cosmetic result	4	2%
Keloid / hypertrophied scars	1	<1%
Manchester scar scale: visible scar on abdomen	3	2%
(Number of) visible scars on the abdomen	2	1%
Postoperative appearance of umbilicus	1	<1%
Scar appearance on the abdomen	1	<1%
Scar appearance on the abdomen after 1 week	1	<1%
Scar appearance on the abdomen after 4 months	1	<1%
Scar appearance on the abdomen after 8 months	1	<1%
Liver biochemistry: normal or abnormal	2	1%
Fecal calprotectin levels	1	<1%
Plasma alanine transferase levels (ALT/ALAT)	2	1%
Albumin	1	<1%
Bilirubin	2	1%
Liver histology	2	1%
C-kit positive cells	1	<1%
NeuN expression	1	<1%
Number of CD4positive T-lymphocytes	0	0%
Number of CD4positive T-lymphocytes	1	<1%
Ratio of CD4/CD8 T lymphocytes	1	<1%
Level of pro-inflammatory cytokines TNF-a, IFN-y and IL-6	1	<1%
Level of anti-inflammatory cytokine IL-10	1	<1%
Time (in hours) until first passage of flatus	3	2%
Time (in hours) until first defecation	4	2%
Time to recovery of peristalsis	1	<1%
Normal urine cultures	1	<1%
Normal urine creatinine	1	<1%
Normal serum creatinine	1	<1%
Level of K+	1	<1%
Level of Na+	1	<1%
Level of Cl-	1	<1%
Level of HCO3-	1	<1%
Level of Hb	2	1%
Level of albumin	4	2%
Level of prealbumin	2	1%
Level of retinol binding protein	1	<1%
Level of globulin in serum	1	<1%
IgA level	1	<1%
Transferrin level	1	<1%
Vitamin b12	1	<1%
Folic acid in serum	1	<1%

			J
0	₹		
	Ĺ	/	
	(		3
5			5
ď			
	τ		5
	Ċ		
	Ļ		J
	2		
	,		

pH in stool	1	<1%
Glucose in stool	1	<1%
Hemoccult test in stool	1	<1%
Calprotectin in stool	1	<1%
Mean arterial pressure (MAP)	1	<1%
Heart rate	1	<1%
Saturation (SpO2)	1	<1%



Table 1: Study characteristics of included publications			
		n =	%
Originated in	Africa	6	(3%)
	Asia	99	(49%)
	Europe	62	(31%)
	Eurasia	2	(1%)
	North America	23	(12%)
	Oceania	5	(3%)
	South America	2	(1%)
	Intercontinental	1	(1%)
Study timing	Retrospective	130	(65%)
	Prospective	30	(15%)
	Cross-sectional	39	(19%)
	Mixed design	1	(1%)
Type of study	Observational	120	(60%)
	Comparative	80	(40%)
Study design	Cohort	179	(90%)
	Case series	6	(3%)
	Case-control	7	(3%)
	Trial	8	(4%)

Study scale	Single-center	150	(75%)
	Multi-center	33	(17%)
	National	17	(8%)
Year of publication	2015	16	(8%)
	2016	20	(10%)
	2017	27	(13%)
	2018	27	(13%)
	2019	33	(17%)
	2020	38	(19%)
	2021	39	(20%)
Number of included patients	<25	36	(18%)
	25-100	102	(51%)
	101-300	34	(17%)
	301-1000	17	(9%)
	>1000	11	(5%)

**Table 2:** Identified studied parameters in HSCR research appearing in >5% of the included articles

		n =	%
Baseline characteristics	Sex	176	(88%)
	Age at surgery	132	(66%)
	Extent of aganglionosis <sup>a</sup>	101	(51%)
	Syndromal, genetic and chromosomal	80	(40%)
	disorders		
	(of which) Trisomy 21	65	(33%)
	Age at follow-up	71	(36%)
	Associated anomaly (cumulative)	58	(29%)
	Initial clinical symptoms (cumulative)	55	(28%)
	Gestational age or prematurity	45	(23%)
	Enterocolitis (preoperative)	45	(23%)
	Birth weight	42	(21%)
	Cardiovascular anomalies	40	(20%)
	Weight at surgery	37	(19%)
	Age at diagnosis	34	(17%)
	Family history of HSCR <sup>b</sup>	28	(14%)
	Delay in evacuation/passage of meconium		

	Congenital heart disease	25	(13%)
	Renal/genitourinary anomalies	25	(13%)
	Abdominal distention (preoperative)	23	(12%)
	Constipation (preoperative)	19	(10%)
	Neurologic anomalies	19	(10%)
	Gastrointestinal anomaly <sup>c</sup>	19	(10%)
	Ethnicity	19	(10%)
	Vomiting (preoperative)	18	(9%)
	Age at presenting symptoms	17	(9%)
	Poor feeding/malnutrition/failure to thrive	15	(8%)
	(preoperative)	14	(7%)
	Congenital anomalies of the urogenital		
	system	13	(7%)
	Pulmonary/respiratory anomalies		
	Intestinal perforation (preoperative)	12	(6%)
	Congenital anomalies of the nervous system	10	(5%)
		10	(5%)
Diagnostics, treatment	Type of repair	113	(57%)
and care process	Duration follow-up	78	(39%)
	Preoperative / primary stoma	71	(36%)

	Operative time (pull-through)	46	(23%)
	Blood loss (pull-through)	41	(21%)
	Laparoscopy or laparotomy or transanal	40	(20%)
	approach		
	Length of resected aganglionic and dilated	40	(20%)
	segments		
	Anal dilatations (preoperative)	33	(17%)
	Contrast enema (preoperative)	27	(14%)
	Rectal biopsies (preoperative)	26	(13%)
	Follow-up rate	21	(11%)
	Preoperative / primary colostomy	20	(10%)
	Single- or multiple staged procedure	19	(10%)
	Daily preoperative colon irrigations	18	(9%)
	(mechanical bowel preparation)		
	Intraoperative biopsies at time of pull-	18	(9%)
	through	18	(9%)
	Intraoperative complications (pull-through)	16	(8%)
	Preoperative / primary ileostomy	14	(7%)
	Conversion laparoscopy to laparotomy (pull-		
	through)	14	(7%)

	ACE d	13	(7%)
	Anorectal manometry (preoperative)	12	(6%)
	Postoperative anal dilatation under general		
	anesthesia	12	(6%)
	Anorectal manometry: follow-up	11	(6%)
	Time to start oral feeding		
Outcome	Postoperative Hirschsprung Associated	127	(64%)
	Enterocolitis (HAEC°)		
	Fecal incontinence	107	(54%)
	Constipation	96	(48%)
	(Any) reoperation	85	(43%)
	Anastomotic stricture/stenosis	76	(38%)
	Soiling	72	(36%)
	Length of primary hospital stay	71	(36%)
	Anastomotic leakage	56	(28%)
	Bowel function (standardized scoring)	54	(27%)
	Mortality	53	(27%)
	Defecation frequency	52	(26%)
	Intestinal obstruction	49	(25%)
	Gastrointestinal symptoms during follow-up	40	(20%)

	Perianal issues (cumulative)	38	(19%)
	Normal defecation function	37	(19%)
	Use of bowel regulating medication	32	(16%)
	Growth/weight/failure to thrive during	32	(16%)
	follow-up		
	Wound issues (cumulative)	32	(16%)
	Permanent stoma	31	(16%)
	Botulinum toxin	31	(16%)
	Quality of life	28	(14%)
	Complications (mentioned as such)	28	(14%)
	Urinary function	27	(14%)
	Wound infection	27	(14%)
	Early postoperative complications	26	(13%)
	(mentioned as such)		
	Readmission	25	(13%)
	Anal excoriations	24	(12%)
	Residual aganglionosis	24	(12%)
	Stoma at time of follow-up	21	(11%)
	Bowel function score, Rintala et al. <sup>17</sup>	20	(10%)
	lleus/bowel obstruction due to adhesions	20	(10%)

	Abdominal distension	18	(9%)
	Difficulties with socializing/social	18	(9%)
	adaptation/relationships		
	Cause of death	17	(9%)
	Fecal contamination/fecal accidents	17	(9%)
	HAEC treated by conservative management	16	(8%)
${}^{A}$	Constipation manageable with laxatives	15	(8%)
	Form/consistency of stool	15	(8%)
	Rectal prolapse	15	(8%)
	Stoma complications (cumulative)	15	(8%)
	Constipation manageable with enema(s)	14	(7%)
	Multiple episodes of enterocolitis	14	(7%)
	HAEC recurrence	14	(7%)
	Weight at time of follow-up	13	(7%)
	Feeling the need for defecation	13	(7%)
	Ability to hold back defecation	13	(7%)
	Use of enemas	13	(7%)
	Use of laxatives	13	(7%)
	Sepsis	13	(7%)

	Incidence of HAEC	13	(7%)
	Diarrhea	12	(6%)
	Constipation manageable with diet	12	(6%)
	Recurrent constipation	12	(6%)
	Wound dehiscence	11	(6%)
	Fever	10	(5%)
	Problems with urinary incontinence	10	(5%)
	Reoperation type	10	(5%)
	Reoperation due to complications	10	(5%)
	(cumulative, no timeframe)		
	Reoperation due to obstruction/occlusion	10	(5%)
	(Any) reoperation due to residual	10	(5%)
	aganglionosis		
	Abscess	10	(5%)
	Infection (cumulative)	10	(5%)
	Incomplete/transitional zone pull-through	10	(5%)
		7	

<sup>&</sup>lt;sup>a</sup> Extent of aganglionosis refers to the histological level of transitional zone, namely rectal, sigmoid, rectosigmoid, distal descending colon.

<sup>&</sup>lt;sup>b</sup> HSCR: Hirschsprung's disease

<sup>c</sup>Gastrointestinal anomalies: excluding Hirschsprung's disease

<sup>d</sup> ACE: Antegrade Colonic Enema

<sup>e</sup> HAEC: Hirschsprung-associated enterocolitis



**Table 3.** Identified tools/instruments utilized and reported in one or more included publications.

		N=	%
Incontinence scores	Wingspread criteria	4	(2%)
	Miller incontinence score	2	(1%)
	Baylor Continence Scale	2	(1%)
	Postoperative Fecal Incontinence Score	1	(<1%)
	Jorge-Wexner score	1	(<1%)
	Visick score	1	(<1%)
	Continence evaluation score	1	(<1%)
Scores for bowel	Bowel function Score (Rintala et al.) <sup>17</sup>	20	(10%)
function	Bowel Function Score according to	7	(4%)
	Holschneider		
	Krickenberg classification system	6	(3%)
	Pediatric Incontinence and Constipation	3	(2%)
	Scoring System		
	Stooling Survey (El Sawaf et al.)	3	(2%)
	Evacuation score of the Japan Society of	2	(1%)
	ARM Study group		
		2	(1%)

_			
	Vancouver Dysfunctional Elimination Syndrome Survey (VDESS)	1	(1%)
	Bowel Function Score according to		
	Holschneider, adapted by Lindahl et al	1	(<1%)
	Bowel Habit Diary	1	(<1%)
	Kelly Scale Score for recovery of bowel		
	function	1	(<1%)
	Postoperative bowel function score	1	(<1%)
	HSCR anal function criteria (proposed by	,	
	Reding)	1	(<1%)
	Wingspread score	1	(<1%)
	Rome IV criteria		
Motor- and neurologic	Intelligence (Rakit   WISC-III-NL)	1	(<1%)
development and behavior	Memory (WISC-III)	1	(<1%)
	Attention (Dot cancellation test)	1	(<1%)
	Self-esteem (SPPC)	1	(<1%)
	WISC IV	1	(<1%)
	NEPSY	1	(<1%)
	Kidscreen 10	1	(<1%)

Sexual function	International index of Erectile Function	1	(<1%)
	Female sexual functioning index	1	(<1%)
	Female sexual distress scale	1	(<1%)
	Sexual education questionnaire	1	(<1%)
	Normal erectile functioning (Erectile	1	(<1%)
	Hardness Score)		
Hirschsprung's	HAEC score (by Pastor et al.)	5	(3%)
associated enterocolitis	Grading system by Elhalaby et al.	3	(2%)
scores	Grading system by Murphy et al.	1	(<1%)
Quality of life	Pediatric Quality of Life Inventory (PedsQL)	8	(4%)
	Short Form 36 (SF-36)	5	(3%)
	HSCR and ARM QoL scale (HAQL)	4	(2%)
	Gastrointestinal Quality of Life Index	4	(2%)
	(GIQLI)	2	(1%)
	Peds QoL Family Impact Module	2	(1%)
	Fecal Incontinence and Constipation		
	Quality of Life	2	(1%)
	Child Health Questionnaire-Child Form 87		
	items (CHQ-CF87)	2	(<1%)

World Health Organization Quality of Life		
100 (WHOQOL-100)	1	(<1%)
Peds QoL Generic Core Scale	1	(<1%)
Peds QoL General Wellbeing Score	1	(<1%)
WHO QOL-BREF	1	(<1%)
Assessment of QoL in Children and		
Adolescents with fecal incontinence		
(AQLCAFI)	1	(<1%)
Child Health Questionnaire - Parent Form	,	
50 (CHQ-PF50)	1	(<1%)
Scoring system by Bai et al. in patients with		
HD	1	(<1%)
Barrena score	1	(<1%)
Taiwanese Child and Caregiver Quality of	1	
Life (TCCQOL)	1	(<1%)
Hirschsprung's Disease/Anorectal		(<1%)
Malformation Quality of life Questionnaire	1	
(HAQL)		(<1%)
KIDSCREEN 52		

Skin and subcutaneous

Manchester scar scale

<sup>a</sup> Multiple instruments or tools may have been used in one publication.

(2%)

3